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Abstract 
 
 Enhancing the physicochemical properties of solid-state materials through crystal 
engineering enables optimization of these materials without covalent modification. 
Cocrystals have become a reliable means to generate novel crystalline forms with 
multiple components and they exhibit different physicochemical properties compared to 
the individual components. This dissertation exemplifies methodologies to generate 
cocrystals of active pharmaceutical ingredients (API’s) based upon knowledge of 
supramolecular interactions (supramolecular synthons), while focusing on enhanced 
delivery through in vitro and in vivo processes with both salts and cocrystals respectively. 
 The utility of mechanochemistry involving small amounts of an appropriate 
solvent, or solvent drop grinding (SDG), has been shown to reliably reproduce cocrystals 
with the anti-convulsant carbamazepine that were originally obtained by solution 
crystallization. This technique has been confirmed as a reliable screening method using 
solvents in which both components exhibit some solubility. The benefits of this technique 
lie in the time and cost efficiency associated with it as well as its inherently small 
environmental impact making it a “Green” method. SDG was also used as an efficient 
way to discover cocrystals of the anti-inflammatory meloxicam with carboxylic acids 
after analysis of existing reports and the analysis of structural data from the Cambridge 
Structural Database (CSD) to guide the choice of coformer. It has been shown that SDG 
can be used to screen for cocrystalline forms that are also obtainable by solution 
xiii 
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crystallization which is important in later stage development and manufacturing including 
but not limited to large scale up processes. Single crystals suitable for single crystal X-
ray diffraction were obtained with meloxicam and two of the coformers, fumaric and 
succinic acid. Some of the meloxicam cocrystals exhibited enhanced pharmacokinetic 
(PK) profiles in rats exemplifying significantly higher serum concentrations after only 
fifteen minutes and consistently higher exposure over the time studied while others 
maintained lower exposure. This reveals that cocrystals can fine tune the PK profile of 
meloxicam in order to reduce or enhance exposure. 
 Two different sulfonate salts, 4-hydroxybenzenesulfonate (p-phenolsulfonate) and 
4-chlorobenzenesulfonate, of the anti-spastic agent (R,S) baclofen were developed by 
strategically interrupting the intramolecularly stabilized zwitterionic structure of 
baclofen. This zwitterionic structure results in low solubility associated with 
physiological pH required for intrathecal administration. Structural data for both salts in 
the form of single crystal X-ray diffraction data was successfully obtained. Solubility 
based on baclofen was assessed and shown to increase in pure water and at pH’s 1 and 7. 
Only the 4-chlorobenzenesulonate salt maintained an increased solubility over two days 
at pH 7 making it a viable candidate for further study in terms of intrathecal 
administration. During crystallization experiments with (R,S) baclofen two polymorphic 
forms of the baclofen lactam were generated, Forms II and III. Both forms are 
conformational polymorphs confirmed by single crystal X-ray diffraction and Form II has 
a Z’ of 4 with an unusual arrangement of enantiomers. 
  
 
Chapter 1: Introduction 
1.1 Supramolecular Chemistry 
1.1.1 van der Waals Forces 
When two atoms come together to form a molecule (e.g. N2) they are held 
together by a covalent bond, which can be described as sharing of electron density that is 
delocalized over the entire molecule resulting in a strong chemical bond.1 The interaction 
of atoms or molecules with one another is the fundamental basis for the physical state in 
which they exist under ambient conditions and ultimately affects their physicochemical 
properties.  Johannes Diderik van der Waals was born in 1837 in the Netherlands and 
was one of the first professors of physics at the University of Amsterdam, then called 
Athenaeum Illustre of Amsterdam. During van der Waals’s work towards understanding 
the different phases of physical chemistry he published the van der Waals equation of 
state that contained a constant related to the strength of attraction between species.2 The 
idea of intermolecular attractive forces were considered earlier by Borelli and Jurin with 
respect to capillary action where they explain their results by attractive forces between 
the molecules of the tube and the liquid.3 Once the existence of these forces was 
accepted, explanations were sought after. Debye suggested molecules have a deformable 
distribution of charge and are therefore this distribution is not rigid and can be polarized 
in an external electromagnetic field resulting in attractive forces if the field is non-
uniform.4 For molecules with dipoles and quadrupoles in the gaseous state at low 
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temperature Keesom’s alignment effect was developed, which says that as a molecule 
rotates and moves in space it will frequently collide with another molecule resulting in 
the molecules positioning in such a way that they are caught in an attractive position.5 
Debye’s theory fills in the gaps for the persistence of van der Waals forces at higher 
temperatures not accounted for by Keesom. For nonpolar molecules the very weak 
attractive van der Waals forces can be explained by London Dispersion forces which are 
related to the deformable distribution of charge mentioned earlier, whereby temporary 
very weak dipoles are formed resulting in electrostatic attraction.3 This work led to the 
measurement and reporting of van der Waals volumes and radii in 1964 once X-Ray 
diffraction data of crystalline materials became sufficiently available and as of 2010 the 
manuscript has been cited 10,767 times.6 X-ray diffraction is now considered the “gold 
standard” for the characterization of solid-state materials. van der Waals equation of state 
has been updated several times to account for progress in the field of physical chemistry 
to its current status as the Elliott, Suresh, Donohue equation of state.7 These forces can be 
summed up as weak non-directional electrostatic interactions usually less than 5 kJ/mol.8 
1.1.2 Coordination Chemistry 
 The stronger side of electrostatic interaction involves charged species i.e. ionic 
bonds and coordination bonds also known as coordinate covalent. Coordination 
chemistry involves a metal ion coordinating with a donating ligand. The ligand in this 
case can be organic and can be negatively charged, as in the case of a carboxylate, or 
contain a lone pair of electrons, as in the case of the nitrogen atom of 4, 4’-bipyridine. 
For the neutral pyridine molecule there is a dipole – ion interaction with the positive 
charge on the metal, which may be considered a coordinate covalent bond. These 
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interactions can lead to discrete structures, polymers, and three-dimensional (3D) 
networks depending on the different coordination geometries of the metal employed but 
are not considered completely covalent in nature because they are reversible.9 These 
coordination polymers can have porosity or cages similar to zeolites and when organic 
ligands are used they are termed metal organic frameworks (MOFs).10  
1.1.3 Hydrogen Bonding  
A hydrogen bond (H-Bond) can be described as an exaggerated dipole – dipole 
interaction in which a hydrogen atom is attached to an electronegative atom and is 
attracted to another dipole in close proximity, in what is termed a donor (D)– acceptor 
(A) relationship, where the atom covalently linked to the proton (H) is the donor. The 
relationship can be generally described by, D-H•••A. Linus Pauling described the H-bond 
as electrostatic in nature early on and he believed the donor atom and the acceptor atom 
needed to be sufficiently electronegative in order to have enough electrostatic attraction 
to result in a bond.11 H-bonds are strong and directional by nature compared to van der 
Waals forces with bond energies ranging from 4 – 120 kJ/mol.8 The weaker end of the H-
bond energy spectrum merges into van der Waals forces where there lies a grey area 
between the two.12 
  
1.1.4 Supramolecular Chemistry and its Biological Significance 
Other intermolecular interactions include C-H•••π, π•••π stacking, and cation•••π 
interactions.8 All of these intermolecular interactions including those mentioned in the 
two previous sections can lead to self assembled aggregates called supermolecules, where 
there lies a host guest type of interaction.13 The term supermolecule dates back to 1949 
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when the term “übermolekeln” was used for an intermolecular complex.14 This self 
assembly based on intermolecular interactions is termed supramolecular chemistry by 
Jean-Marie Lehn which he defined as follows, “Supramolecular chemistry may be 
defined as chemistry beyond the molecule, bearing on the organized entities of higher 
complexity that result from the association of two or more chemical species held together 
by intermolecular forces.”15 Supramolecular chemistry could be traced back to 
investigations into receptor binding in biological systems when a “lock and key” model 
was described by Emil Fischer.16 H-bonding is the lead intermolecular force directing self 
assembly involving organic compounds and has been described as the “masterkey 
interaction” in supramolecular chemistry.8 Each of the intermolecular interactions 
described can affect supramolecular self assembly and their bond energies are compared 
in Table 1.1. Although H-bonds are usually the primary directing interaction for self 
assembly, other weaker intermolecular interactions can serve to stabilize the resulting 
structure. 
Table 1.1: Selected bond energies for comparison. 
Bond Type Bond Energy (kJ/mol)
Covalent 150-450 
Ionic 100-350 
Ion - Dipole 50-200 
H-Bond 4-120 
π - Cation 5-80 
Dipole-Dipole 5-50 
π –π Stacking <50 
van der Waals <5 
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  Using nature as a template for instruction and molecular recognition, the field of 
supramolecular chemistry has included research involving crown ethers17-18, host guest 
systems19-20, cryptands21-22, and cavitands.23 One of the most important discoveries in 
biological sciences was the determination of the structure of deoxyribonucleic acid 
(DNA),24 which consists of nucleotide polymers connected via phosphodiester backbones 
that H-bond between base pairs creating a double helix. This genetic material is necessary 
for cellular replication and the polymeric strands must be unwound in order to be 
decoded and translated into instructions for cellular components, therefore a reversible 
supramolecular process is necessary to read the DNA. H-bonding and supramolecular 
recognition are necessary for many biological functions including but not limited to 
receptor binding, immunological responses, protein folding and function, and 
coordination bonds responsible for hemoglobin’s ability to transport oxygen.8 
 
1.2 Crystal Forms 
1.2.1 Single Component Molecular Crystals 
 Molecules tend to arrange themselves into regular repeating units in the solid state 
creating a 3D molecular array which is defined as a crystal. If there is no regular 
repeating unit the solid is termed amorphous, for example glass. Amorphous compounds 
are known to be unstable and reactive compared to their crystalline counterparts.25 An 
example of a molecular crystalline substance is table sugar which consists of sucrose 
crystals. The regular repeating 3D unit of a crystal is termed the unit cell and the way 
molecules arrange themselves inside the unit cell is referred to as crystal packing. 
Crystals can vary in size from a few nanometers to meters26 and exhibit a particular shape 
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or morphology. The points in the unit cell that define where molecules reside can be 
referred to as the crystal lattice. The crystal lattice can be simplified to a 3D box with 
points inside representing lattice points and if those points were spheres then different 
centering within the box will determine where other points can reside. There are 7 ways 
in which a lattice can arrange in the unit cell, called a crystal system, and when combined 
with different lattice centerings the result is 14 Bravais Lattices (infinite set of points 
generated by discrete translations) and within these  there are only 230 possible 
arrangements called space groups, which are based on mathematically generated 
symmetry operations.25 The study and determination of crystal structures comprises the 
field of crystallography and Z is defined as the number of formula units in the unit cell, 
while Z’ is the number of formula units in the crystallographic asymmetric unit. Z’ can be 
strictly defined as the number of formula units in the unit cell divided by the number of 
independent general positions.27 Covalent network solids containing only one type of 
atom, diamond for example, should also be mentioned, however, due to the scope of this 
manuscript they are not discussed further. 
 
1.2.2 Salts 
 A crystalline salt is an ionic solid involving a charge-charge interaction between 
ions of opposite charge. Organic and inorganic salts, like sodium chloride composed of 
alternating sodium and chloride ions, are held together solely by very strong electrostatic 
interactions. An organic salt can result from ionizable functional groups or in 
combination with permanent charge states as in a quarternary nitrogen atom carrying a 
positive charge. Primary, secondary, or tertiary ammonium salts are examples of charge 
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assisted H-bonds28, which typically contain ion-dipole electrostatic interactions with bond 
energies between those of ionic bonds and H-bonds as exemplified in Table 1. Inorganic 
ions can also readily pair with organic ions as is the case of pharmaceutical hydrochloride 
salts.  
 
1.2.3 Other Multiple Component Crystals: Solvates, Hydrates, and Cocrystals 
 When more than one entity or molecule crystallizes together in a stoichiometric 
ratio it is referred to as a multiple component crystal. When a single component 
crystalline material has solvent as part of the crystalline arrangement in a stoichiometric 
ratio the binary crystal is termed a solvate and when water is the solvent involved the 
crystalline form is referred to as a hydrate. In these instances the solvent helps stabilize 
the overall packing of the unit cell. The term cocrystal is used very loosely depending on 
the scientific field it applies to and in terms of solid-state chemistry there is current 
debate about how narrowly or broadly one defines a cocrystal.29-34  For this work a 
narrow definition of cocrystal is applied: a stoichiometric multiple component crystal that 
is formed between two compounds that are solids under ambient conditions in which at 
least one cocrystal former (second molecule) is molecular and forms a supramolecular 
synthon (specific intermolecular interaction to be discussed further in section 1.4.2) with 
the remaining cocrystal former(s).35-36  
 One of the first uses of the term cocrystal in the context of solid-state chemistry 
dates back to 1967 describing the H-bonded complex between 9-methyladenine and 1-
methylthymine, first reported by Hoogsteen.37-38 Cocrystals as defined here began to 
appear in the literature in 1844 via a grinding experiment by Friedrich Wöhler who 
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prepared the 1:1 quinone:hydroquinone cocrystal by “kugelchen” or little ball likely 
referring to a ball mill type of apparatus.39 Cocrystals were not named as such early on 
and over the years many cocrystals were discovered and reported but labeled under 
different nomenclature including molecular complexes40, addition compounds41, organic 
molecular compounds42, heteromolecular crystals43, solid-state complexes44, and 
molecular compounds.45 Both single component and multiple component crystalline 
materials can have the same building blocks arranged in a different manner considered a 
separate crystalline entity of the same molecules or a polymorph.  
 
1.2.4 Polymorphism 
 The generally accepted definition of polymorphism is the ability of a compound 
to exist in more than one crystalline state. Bernstein, however, provides a more narrow 
definition limited by what he considers as “safe” criterion for classifying polymorphic 
systems which states, “classification of a system as polymorphic would be if the crystal 
structures are different but lead to identical liquid and vapor states”.46 
Pseudopolymorphism is a term McCrone proposed which he defines as, “a convenient 
term to use to describe a variety of phenomena sometimes confused with polymorphism. 
They include desolvation, second-order transitions (some of which are polymorphism), 
dynamic isomerism, mesomorphism, grain growth, boundary migration, re-crystallization 
in the solid state and lattice strain effects.”47A prototypical example of a polymorphic 
system would be 5-methyl-2-[(2-nitrophenyl)-amino]-3-thiophenecarbonitrile, also 
known as ROY, which exhibits red, orange, and yellow polymorphs.48-49 For organic 
crystals there are two main types of polymorphism; packing polymorphism, which refers 
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to the 3D arrangement of individual molecules with respect to one another, and 
conformational polymorphism, which involves molecules that can adopt different 
geometries through rotation about single bonds, bond stretching/compressing, and 
bending of bond angles.50 Conformational polymorphism began to appear in the literature 
in the 1970’s.51-52 Different molecular geometries that lead to conformational 
polymorphism in order to satisfy a particular solid-state arrangement under a particular 
set of physical conditions can often lead to structures with more than one symmetry 
independent molecule, Z’ > 1. It should also be noted that intramolecular and 
intermolecular interactions can affect both conformation and packing characteristics and 
therefore also play a role in polymorph control. There are two types of polymorphic 
systems with respect to polymorphic transformations, monotropic and enantiotropic.46 
Considering for the sake of discussion that there are two polymorphs, A and B, 
monotropic systems represent a situation where once A has converted to B the 
transformation is irreversible, while enantiotropic systems are reversible. According to 
McCrone’s statement, “the number of forms known for a given compound is proportional 
to the time and money spent in research on that compound,” there are virtually endless 
possibilities and likely there is great validity in this statement, however, existing literature 
and databases do not represent the full scope of polymorphs discovered since many 
structures may not be of interest and not reported, therefore it is difficult to confirm. 
Polymorphism as a whole is an important phenomenon with respect to intellectual 
property and physicochemical properties especially with respect to pharmaceutical 
science.25, 46, 53-54 
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1.3 Solid-State Characterization 
 X-ray diffraction is the “gold standard” for solid-state characterization but 
multiple other complimentary techniques such as attenuated total reflectance Fourier 
transform infrared spectroscopy (ATR-FTIR), Raman spectroscopy, solid-state nuclear 
magnetic resonance (SS NMR), microscopy, differential scanning calorimetry (DSC), 
and thermal gravimetric analysis (TGA) are used in conjunction.25 X-ray diffraction is 
well suited for solid phase characterization due to the X-ray region of electromagnetic 
radiation containing wavelengths smaller than the diameter of an atom since the 
principles of optics dictate that the wavelength of light used to observe an object must be 
smaller than the object itself.55 This is only part of the story however because no lens 
exists that can focus X-rays and therefore creating a direct image is not possible. Since X-
rays have the ideal wavelength for reflecting off of atoms they can be directed at a crystal 
resulting in scattering of the radiation in a specific manner called a diffraction pattern. 
This was first interpreted by William H. Bragg in 1913 and he developed the Bragg 
equation which remains the basis for this technique, Eq. 1.1.25 
    ݊ߣ               Eq.(1.1) ൌ 2݀ sin ሺߠሻ
This equation states that n, an integer multiple of the wavelength, λ, equals twice the 
distance, d, between planes of atoms multiplied by the sine of the angle of incidence, 
while the intensity of diffraction is determined by the electron density of the atom.  
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This technique is used for single crystal analysis resulting in a single crystal structure 
with the aid of mathematical analysis and is also amenable to powders in which case it is 
known as powder X-ray diffraction (PXRD). PXRD usually only provides a diffraction 
pattern and not a single crystal structure but in  some cases where the diffraction pattern 
intensity is large enough the structure can be delineated mathematically from the 
pattern.56  
 The other techniques mentioned each have their own advantages in diagnosing a 
solid phase. ATR-FTIR utilizes absorption of infrared light based on vibrational 
intramolecular and intermolecular movement which results in a spectral output. New 
intermolecular interactions between molecules results in shifting of peaks or even new 
peaks. The other spectroscopic techniques, SS NMR and Raman spectroscopy 
(measurement of scattering of infrared light), will also result in form specific spectra and 
similarly, significant new intermolecular interactions in a new solid-state phase will cause 
shifts in the spectrum. DSC is a valuable tool for determining heats of fusion and 
resultant enthalpies associated with a specific crystal form and can also be applied to 
study polymorphic behavior such as reversible phase transitions and the presence of 
impurities. TGA is ideal for studying solvates and hydrates as it determines weight loss 
over time upon heating which can delineate the stoichiometry of solvent present and the 
qualitative strength of the interaction. Microscopy is useful in determining crystal 
habit/morphology, twinning in some cases, and with the use of a polarizer, whether the 
crystal is polar. Hot-stage microscopy coupled with other techniques is useful for 
determining polymorphic transformations and single crystal to single crystal transitions.46 
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1.4 Crystal Engineering, Supramolecular Synthons, and the Cambridge Structural 
Database   
1.4.1 Background 
Designing crystalline materials for specified applications via manipulation of 
intermolecular interactions has been established as the field of crystal engineering.9, 57-58 
The term crystal engineering was introduced by Pepinsky in 1955 when he revealed 
controllable unit cell dimensions and symmetries with metal organic complexes.59 This 
nomenclature seemed to be ahead of its time since the development of crystal structure 
determination, or crystallography, as a field was still young. In 1959 the Hoogsteen base 
pair cocrystal structure emerged between 9-methyladenine and 1-methylthymine, which 
was paramount to understanding DNA which utilized Watson-Crick base pairing.37 It 
wasn’t until 1971 that the elegance behind supramolecular chemistry and the possibility 
of engineering crystalline forms came to fruition in the literature with Schmidt’s report 
on photodimerization in the solid state with cinnamic acids further studied by 
MacGillivray in 2000 utilizing a cocrystal template as depicted in Figure 1.1.60-61 
 
Figure 1.1: Single-crystal to single-crystal photodimerization within a cocrystal. 
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 Guatum Desiraju defined crystal engineering in 1989 as, “the understanding of 
intermolecular interactions in the context of crystal packing and the utilization of such 
understanding in the design of new solids with desired physical and chemical 
properties.”58 The importance of supramolecular chemistry was well defined at this point 
and more attention was paid to understanding intermolecular interactions and how to 
subsequently manipulate those interactions in crystalline materials. Margaret Etter helped 
to develop the field in the late 1980’s and 1990’s by studying cocrystallization and 
analyzing H-bond patterns, which she termed “motifs,” that helped develop graph set 
analysis to define specific H-bonded motifs.62-68 Etter’s contributions helped establish the 
foundation for the current rapid growth of supramolecular chemistry and in 1991 she 
proposes three general rules with regards to H-bonding; 1) all good proton donors and 
acceptors are used, 2) six membered ring intramolecular H-bonds form before 
intermolecular H-bonds, and 3) the best donors and acceptors left after intramolecular H-
bonding will be used for intermolecular H-bonding.63 She includes the following 
statement with regards to her work foreshadowing the importance of physicochemical 
property enhancement through supramolecular chemistry, “We have also shown that 
hydrogen-bonded molecular aggregates can have unexpected properties as a result of the 
collective behavior of these weakly bound molecules.”63  
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1.4.2 Supramolecular Synthons 
 As mentioned in section 1.2.3 supermolecules interact with one another via 
supramolecular synthons which are defined by Desiraju as, “structural units within 
supermolecules which can be formed and/or assembled by known or conceivable 
synthetic operations involving intermolecular interactions.”69 Typically complimentary 
H-bonds act as the supramolecular synthon, although other intermolecular interactions 
are also included. There are two classifications of supramolecular synthons based on 
complimentarity and homogeneity, which are referred to as supramolecular 
homosynthons and supramolecular heterosynthons.70 Figure 1.2 below depicts examples 
of each with respect to carbamazepine (CBZ), an anti-convulsant API.    
 
 
 
 
 
 
 
 
 
                                   a                                                       b 
Figure 1.2: a) Amide•••Amide supramolecular homosynthon between CBZ 
molecules.71 b) Acid•••Amide supramolecular heterosynthon between aspirin and 
CBZ.72 
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When there is self complimentarity between functional groups the result is a 
supramolecular homosynthon and when different functional groups compliment each 
other the result is a supramolecular heterosynthon. It should be noted that the term 
supramolecular mixed homosynthon can be used in the instance where two different 
carboxylic acids interact via an acid•••acid supramolecular homosynthon.73 Examples of 
supramolecular homosynthons are amide•••amide74 and acid•••acid75-76 dimers. 
Carboxylic acid dimers have been mentioned in the literature as early as 1897 when the 
association of acetic acid in benzene was recognized.77 Later work by F. T. Wall in the 
early 1940’s reported the association of benzoic, m-toluic, and o-toluic acid with 
themselves in benzene as individual solutions confirmed by vapor pressure osmometry.78-
79  
 Supramolecular heterosynthons can be exemplified by acid•••amide,68, 80-82 
acid•••aromatic nitrogen (Narom)64, 70, 83-86, alcohol•••amine,87-90 and alcohol•••Narom.91-93 
With crystal engineering in mind it was important to determine which supramolecular 
synthons would persist over others. Synthon competition was assessed by including the 
presence of other functionalities in order to establish which interactions take precedence 
in order to determine the hierarchy. Cocrystals have been particularly important in 
delineating these hierarchies with respect to alcohols, carboxylic acids, Narom, cyanos, and 
amides. Once Etter established some ground rules in terms of H-bonding patterns others 
started to experiment with multiple functional groups present at the same time during 
crystallization. Christer Aakeröy studied whether or not the strongest acid would interact 
with the strongest base and then if the next strongest acid went with the next strongest 
base and so on within their chosen set of molecules.94-97 He also studied ternary 
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cocrystals by employing molecules with carboxylic acid, Narom, and amide functionality 
on the same molecule resulting in acid•••Narom and acid•••amide supramolecular 
heterosynthons.96, 98-99 More reports on this subject soon followed where Bis reveals that 
alcohols prefer to interact with Narom while in the presence of cyano groups.100 Shattock 
then determined that carboxylic acids in the presence of Narom will prefer the 
supramolecular heterosynthon over the homosynthon and that the same theme holds true 
for alcohols in the presence of Narom.101 This study also attemped to distinguish between 
which supramolecular heterosynthon is preferred, however, the findings indicate that both 
heterosynthons occurred for the limited data set utilized leaving this particular piece of 
the hierarchy open for debate for now. Charge assisted H-bonds are also categorized as 
supramolecular synthons28, 102 and are also important in terms of crystal engineering.  
 It has been observed that the carboxylate•••weakly acidic hydroxyl 
supramolecular heterosynthon is persistent in a set of fifteen zwitterionic cocrystals with 
nutraceuticals.103-106 Figure 1.3 below depicts an earlier example of the 
carboxylate•••weakly acidic hydroxyl supramolecular heterosynthon between L-sarcosine 
and L-ascorbic acid which has been deposited into the Cambridge Structural Database 
(CSD).107 
 
Figure 1.3: Carboxylate•••Weakly Acidic Hydroxyl supramolecular heterosynthon, 
CSD Refcode SERASC10 (Serine•••Ascorbic Acid). 
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 Other supramolecular synthons include charge assisted H-bonds with other inorganic ions 
such as phosphate,108  interactions with chlorine of a hydrochloride salt (cocrystal of a 
salt),109 and also halogen bonding, Figure 1.4.110-116 
 
Figure 1.4: Halogen bonded chain between tetrafluoro-1,4-diiodobenzene and 
piperazine, CSD Refcode DIVCUH. 
 
 
1.4.3 The Cambridge Structural Database 
 The CSD represents a large computerized archive of X-ray and neutron 
diffraction data of small (less than 500 non-H atoms) organic and metal organic 
molecules that began in 1965.117-118 This database package of software was developed by 
the Cambridge Crystallographic Data Centre (CCDC) which includes software to 
visualize and analyze molecular interactions including but not limited to bond distances, 
bond angles, symmetry elements, histogram generation, and 3D networks. The CSD 
contains 523,834 entries as of August 2010 and this vast array of structural data has 
become an integral tool for crystal engineering. One simply needs to draw out a proposed 
interaction of interest and a plethora of information is likely to be discovered with 
statistical significance depending on the frequency of occurrence. Each entry is labeled 
with a six letter code, refcode, which may have numbers attached for repeat entries. The  
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robustness of supramolecular synthons can be evaluated if enough data on that particular 
interaction is available. Database mining a very useful tool with regards to solid-state 
chemistry since one can evaluate a very large pool of data not otherwise available from 
one source.9, 119-122 Indeed, much of the work devoted to understanding supramolecular 
synthons and their hierarchies mentioned above was supplemented and even guided by 
CSD analysis and it has now become routine that the initial approach to a crystal 
engineering experiment involves analysis of existing structural data.82, 100-102, 123 
 Crystal engineering has led to the discovery of materials with distinct applications such 
as porous materials124, non-linear optics, pharmaceuticals35, 125, and photographic 
materials.126 An example of the power of the CSD is represented in Figure 1.5, in which 
the average donor-acceptor distance of the carboxylic acid•••Narom supramolecular 
heterosynthon is revealed to be 2.639 Å through histogram generation. 
 
Figure 1.5: D-H•••A (D•••A distance) in Ångstroms for the carboxylic acid•••Narom 
supramolecular heterosynthon. CSD parameters; Aug. 2010 Update, Only Organics, 
R ≤ 0.075, 3D Coordinates Determined, and as drawn in white box. 
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1.4.4 Crystal Structure Prediction 
 Crystal form screening, polymorph control, and molecular design would be 
immensely facilitated if a solid-state chemist could accurately predict the crystalline 
structure of organic molecular crystals. In general, computational approaches search for 
the most thermodynamically stable structure. As remarked by Maddox, “One of the 
continuing scandals in the physical sciences is that it remains in general impossible to 
predict the structure of even the simplest crystalline solids from a knowledge of their 
chemical composition,”127 it remains true that complete and reliable prediction of a 
crystal structure has not been achieved.45, 128-135 The CCDC held the first crystal structure 
prediction workshop in 1999 to evaluate the current state of computational methods and 
the first “blind test” was initiated in which different computational groups were given a 
molecular diagram and asked to predict the crystal structure.128 There have been four 
blind tests to date and the results are increasingly promising as the fourth test concluded 
with dramatic improvements in the success rate of prediction.128, 134, 136-137 The fourth test 
included fourteen groups with four targets in their sites. Thirteen successful predictions 
prevailed overall and for each target at least two groups were successful, while only one 
group got all four as their first choices. There is a long way to go but progress in this area 
is encouraging. 
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1.5 Pharmaceutical Cocrystals 
1.5.1 Synthesis 
 Pharmaceutical cocrystals are defined as multiple component crystals in which at 
least one component is molecular and a solid at room temperature (the coformer), and 
forms a supramolecular synthon with a molecular or ionic active pharmaceutical 
ingredient (API).48, 138 Cocrystals and pharmaceutical cocrystals are identical in terms of 
synthetic routes. Traditional techniques for crystallization apply where supersaturation 
and subsequent nucleation from solution remains to be the most widely accepted method 
and in the case of multiple component crystals the supramolecular synthon between 
individual molecules helps determine the initial aggregate that leads to cocrystal growth. 
Grinding two solids together, or mechanochemistry, to create a new crystalline phase is 
perhaps the simplest way to generate a multiple component stoichiometric adduct or 
cocrystal. It is ideal in terms of cost, environmental impact, and difficulty, and 
furthermore, the addition of small amounts of solvent during the grinding process was 
shown to dramatically increase the kinetics of cocrystal formation in certain cases.36, 139-
140 Grinding can be done by hand with a mortar and pestle or mechanically with a ball 
mill or mixer mill. The melt/cool method involves melting one component followed by 
addition of the second component thereby dissolving it followed by controlling the rate of 
cooling and may be performed in absence of unstable or high melting compounds.141-143 
Slurry methods, which can be facilitated by sonication144, are useful as well and represent 
a method somewhere in between solvent drop grinding and evaporative solution based 
techniques.48, 102, 109 Reaction crystallization is a solution based technique that has been 
specifically applied to cocrystal formation on the premise of manipulating ternary phase 
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diagrams. Reaction crystallization relies upon the cocrystal having a lower solubility in 
the solvent system involved resulting in precipitation of the cocrystal.145 Supercritical 
carbon dioxide can also be used as a unique solvent system to produce cocrystals 
provided the components are soluble.146-147 Less common techniques involve vapor 
diffusion and layering with different solvents/solutions which are more common for 
proteins and MOFs respectively. Each of the methods described above can produce 
pharmaceutical cocrystals and in some cases they will reach the same crystalline form,36 
while in others they may produce polymorphs or even novel forms.148 Crystal 
engineering with pharmaceuticals via the supramolecular synthon approach is successful 
due to the occurrence of functional groups with H-bonding capability, which is related to 
natures use of supramolecular chemistry to regulate biological functions and indeed APIs 
contain lots of H-bonding functionalities, see Table 1.2.149  
  
Table 1.2: Occurrence of H-Bonding functional groups in the top 100 prescription 
APIs. 
Functional 
Group 
% of Top 100 APIs 
Alcohol 39 
Tertiary Amine 37 
Carbonyl 35 
Ether 33 
Secondary Amine 31 
Carboxylic Acid 30 
Ester 22 
Narom 12 
Secondary Amide 11 
Sulfonamide 3 
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1.5.2 History 
 The existence of pharmaceutical cocrystals goes very far back in time, however, 
their importance has only recently been appreciated as highlighted by Zaworotko and 
Shan as, “long known but little studied.” 138 It should be noted that the following is not a 
comprehensive timeline but rather a description of important events that led to the current 
state of pharmaceutical cocrystals.  One of the first appearances of pharmaceutical 
cocrystals in the literature resides in a French patent describing molecular complexes 
between barbiturates and amino pyridines.150 Barbiturates are central nervous system 
depressants and years later, 1968 – 1974, more complexes with barbiturates surfaced.151-
154 Almost concurrently theophylline cocrystals with chlorosalicylic acid and 
sulfathiazole are reported by Shefter.155-156 Theophylline acts as a bronchodilator and 
sulfathiazole is an antimicrobial so it seems highly likely that synergism was factor of 
interest for bacterial lung infections. These APIs seemed to have drawn attention to 
pharmaceutical cocrystals, although they were seen as complexes at the time, which 
remains a correct chemical description. Since then other theophylline, sulfa drug, and 
barbiturate pharmaceutical cocrystals continued to be reported throughout the 1980’s 
early 1990’s.157-163 Caira reported complexes with sulfonamides including benzoic acids 
and salicylic acids as coformers with synergism in mind.164-165 In 1992 Zerkowski and 
Whitesides report a complex between melamine and cyanuric acid which would later 
become very important.166 In 2007 there was a pet food recall due to Chinese protein 
export contamination in which melamine:cyanuric acid cocrystals crystallized out in the 
kidneys of animals causing death in many instances.167 It is known that cyanuric acid can 
be produced by hydrolysis of melamine, which was added to the pet food to falsely 
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mimic proteinogenic amino acids resulting in an inflated protein content analysis. In 2008 
this same phenomenon caused the Chinese baby milk scandal that caused thousands of 
Chinese babies to get sick while some even lost their lives.168-169 Reverting back to 1993 
the highly prescribed antidepressant Depakote®, which was actually a cocrystal of salt 
between two sodium hydrogen divalproate oligomers, was patented due to its superior 
stability compared to the free acid or the monomeric sodium salt, Figure 1.6.170 
 
 
Figure 1.6: Sodium hydrogen divalproate oligomer. 
 
 Throughout the 1990’s and the early 2000’s more examples of pharmaceutical 
cocrystals continued to emerge as the advent of crystal engineering began to take hold.68, 
171-178 In 2003 and 2004 the importance of these pharmaceutical compositions began to 
take hold in the patent landscape with the realization that the physicochemical properties 
of a molecule can be significantly changed without covalently changing the molecule.179-
182 A seminal article by Zaworotko in 2003 sparked lots of interest in what is now the 
most studied API in terms of pharmaceutical cocrystals, the anticonvulsant CBZ. The 
interest in CBZ grew rapidly and has resulted in the production and analysis of dozens of 
multiple component forms.145, 183-188 Later in the year Zaworotko also reported multiple 
component pharmaceutical phases based on the carboxylic acid•••Narom supramolecular 
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synthon with 4,4’-bipyridine and the non-steroidal anti-inflammatories (NSAID’s) 
aspirin, ibuprofen and flurbiprofen.70 It wasn’t until 2004 that the term pharmaceutical 
cocrystal is coined by Almarsson and Zaworotko and used from there on out.35 
 
1.5.3 Crystal Form Impact and Physicochemical Property Manipulation 
“Over 90% of all pharmaceutical products, such as tablets, aerosols, capsules, 
suspensions, and suppositories contain drug in particulate, generally crystalline 
form.”189SmithKline Beechum R&D News 
 
Unique crystalline forms tend to exhibit distinctive physicochemical properties 
effecting the dissolution, manufacturing, physical stability, permeability, and oral 
bioavailability of an API.190-192 Aqueous solubility of APIs is indispensible for their 
optimal bioavailability and efficacy. The rate limiting step for absorption of an API in an 
oral dosage form can be the dissolution of that API in the gastrointestinal (GI) tract. 
Some of the earliest dissolution experiments were conducted and published by Arthur A. 
Noyes and Willis R. Whitney in 1897193 where they proposed that the rate of dissolution 
is proportional to the difference of concentration at time t and the saturation solubility 
governed by Eq. (1.2) below. 
                                                  dx  = C(CS -x) Eq.(1.2) 
                                                   dt 
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In Eq.(1.2) C denotes a constant, x denotes the concentration at time t, and CS denotes the 
solubility. The constant, C, in this equation assumes that all systems behave similarly 
however each individual compound will have different rates of diffusion based on its 
respective physical properties including but not limited to electrostatics. This 
mathematical model for their observation as a general law was modified by Bruner and 
Tolloczko in 1900194 to include surface area (S) and then further by Nernst and Brunner 
in 1904195-196 to include a diffusion coefficient (D), the thickness of the diffusion layer 
(h), and the volume of the dissolution medium (V) as shown in Eq. (1.3).  
 
                                                   dx = DS (CS – x)  Eq.(1.3) 
        dt     Vh 
 
The advent of this equation was guided by Fick’s second law which predicts how 
diffusion changes the concentration field i.e. changes in the concentration gradient.197 
These relationships are related to how kinetics can affect solubility and will dictate how 
fast an API will dissolve and subsequently be absorbed.  
The Biopharmaceutics Classification System (BCS) rates APIs on a scale from 
class I - IV based on solubility and permeability198 and when a compound is deemed class 
II, for example, it is said to have high permeability and low solubility. Class II 
compounds represent a situation where absorption is primarily limited by the rate of 
dissolution and since in Eq. (3) x is negligible compared to CS, sink conditions are 
created. It could also be inferred that the dissolution rate is more important than the 
thermodynamic solubility since absorption prevents saturation in GI fluids not to mention 
dissolution must occur before the thermodynamic solubility can be reached. The FDA 
guidance on BCS class designation is highlighted on the next page,149 although it has 
recently been suggested by Zaki and Bergström that modification of this classification 
system may be necessary to reflect in vivo behavior more accurately.199 
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• Class I - High Permeability, High Solubility 
Class II - High Permeability, Low Solubility 
Class III - Low Permeability, High Solubility 
Class IV - Low Permeability, Low Solubility 
• A drug substance is considered HIGHLY SOLUBLE when the highest dose 
strength is soluble in < 250 ml water over a pH range of 1 to 7.5.  
• A drug substance is considered HIGHLY PERMEABLE when the extent of 
absorption in humans is determined to be > 90% of an administered dose, 
based on mass-balance or in comparison to an intravenous reference dose.  
• A drug product is considered to be RAPIDLY DISSOLVING when > 85% of 
the labeled amount of drug substance dissolves within 30 minutes using USP 
(US Pharmacopeia) apparatus I or II in a volume of < 900 ml buffer solutions.  
 When salt formation, amorphous dispersions, particle size reductions, and 
formulation changes fail to improve solubility and subsequent bioavailability the more 
recent technology of pharmaceutical cocrystallization can be employed. Amorphous 
compositions are typically more soluble than their crystalline counterparts but are much 
less stable in the solid state as they tend to revert to more thermodynamically stable 
crystalline compositions,192 therefore their use to improve solubility is not desired if other 
crystalline options exist. Dissolution rate can be either increased or decreased depending 
on the particular crystalline form.143 In 2003 Transform Pharmaceuticals, Inc. reported 
cocrystals between cis-itraconazole, an anti-fungal, and carboxylic acids with improved 
dissolution profiles compared to pure API and a comparable profile of corystals with L-
malic acid or L-tartaric acid against the amorphous marketed form (Sporanox) in 0.1 N 
HCl at 25o C, Figure 1.7.200  
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 Figure 1.7: Dissolution profiles into 0.1 N HCl at 25 °C for itraconazole 
pharmaceutical corystals. Squares = Marketed Form , Diamonds = Pure API, 
Upside down triangles = L-Malic Acid Cocrystal, Right side up triangles = Succinic 
acid Cocrystal, and Circles = L-Tartaric Acid Cocrystal.  
 
  
 In 2004 Childs in conjunction with SSCI Inc. divulged the first pharmaceutical 
cocrystal with a hydrochloride salt, fluoxetine HCl with carboxylic acids, with improved 
intrinsic dissolution profiles, Figure 1.8a.109 Another important part of that study was the 
appearance of the “spring and parachute” behavior of certain cocrystals where an initial 
spike in the dissolution profile is followed by a decrease toward the concentration of the 
pure API indicating dissociation of the cocrystal, Figure 1.8b. Dissolution enhancement 
through pharmaceutical cocrystallization continued to be studied and reports have 
continuously surfaced since 2003.108, 143, 188, 201-216 Other important physical properties 
like stability to humidity211, 215, 217-218 and improved compressibility141, 219 have also been 
demonstrated with pharmaceutical cocrystals.  
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Figure 1.8: a) Intrinsic dissolution profiles for fluoxetine HCl pharmaceutical 
cocrystals in water at 10o C. b) Spring and parachute of fluoxetine HCl:succinic acid 
during powder dissolution in water at 20o C.  
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 Pharmaceutical cocrystals represent an opportunity to diversify the number of 
crystal forms of a given API and in turn fine tune or even customize its physicochemical 
properties without the need for chemical (covalent) modification. There is no longer any 
doubt that cocrystals can change the physicochemical properties of a given API, however, 
the way these changes affect the pharmacokinetic (PK) profile is not predictable or fully 
understood due in part to the limited number of animal studies reported in the literature. 
In fact, there are only thirteen case studies in the literature to date, including patent 
literature, which report pharmaceutical cocrystal PK studies in animals.   
 In 2005 Transform Pharmaceuticals, Inc. applied for two patents, both of which 
included animal PK data on pharmaceutical cocrystals. One for modafinil 
(antinarcoleptic) revealed a cocrystal with malonic acid to show an increase in Cmax 
(maximum plasma concentration) and AUC (area under the curve) of about 43% and 
23% respectively when compared to the marketed form, Figure 1.9.220  
 
Figure 1.9: Plasma concentration over time for the modafinil:malonic acid 
pharmaceutical cocrystal over 24 hrs compared to pure API. 
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 The other provided data for itraconazole cocrystals with tartaric acid revealing an 
even greater enhancement reflected by an approximate increase in both Cmax and AUC of 
80% with a reduction of Tmax (time to reach Cmax) by 80% when compared to the 
marketed version which is an amorphous dispersion coated on beads.221 This work was 
followed by McNamara in 2006 when a sodium channel blocker was cocrystallized with 
glutaric acid.  The resulting cocrystal showed a ca. 14-fold increase in plasma Cmax when 
compared to the parent API at 50 mg/kg dose in dogs, Figure 1.10.201  
 
Figure 1.10: Plasma concentration of the glutaric acid pharmaceutical cocrystal 
over time in dogs at 50mg/kg oral dosing compared to parent API, Open Circles = 
Cocrystal, Filled Circles = Pure API . 
 
 Also in 2006 Variankaval in association with Merck & Co., Inc. published a 
phosphodiesterase 4 inhibitor cocrystal with L-tartaric acid.  Due to the lack of single 
crystal X-ray diffraction data, the determination of cocrystal rather than salt was based 
upon ΔpKa and solid state NMR data.  They reported plasma concentrations compared to 
the parent API in rhesus monkeys revealing an approximate 15-fold increase in Cmax and 
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23-fold increase in AUC.202 In 2007 Chen in association with Merck & Co., Inc. reported 
the first inorganic acid cocrystal in which they claim solubility of > 250 mg/mL and 
excellent in vivo performance, however they show no data to back up such claims.108 
2007 also produced an example in dogs where the CBZ:saccharin cocrystal was slightly 
better than the marketed form of CBZ, Figure 1.11.203  
 
Figure 1.11: Plasma concentration in dogs for the CBZ:saccharin pharmaceutical 
cocrystal in a capsule compared to the marketed form immediate release tablet at a 
200 mg dose equivalent for CBZ. 
 
 In 2008 Bak produced an example in which an API: excipient interaction that led 
to the discovery of a cocrystal between sorbic acid and a vanilloid receptor 1 antagonist, 
AMG 517, that proved to have about an 8-fold increase in Cmax and AUC compared to the 
parent API in rats.204 A patent application in 2008 revealed a fumaric acid cocrystal of 
tenofovir disproxil, a reverse transcriptase inhibitor, which showed bioequivalence to the 
marketed form in rats.222 2009 was equally uneventful in producing PK data on cocrystals 
since only one patent application, which originated in Europe as EP 2009010 A1, 
described a C-glycoside derivative - L-proline cocrystal for the treatment of diabetes that 
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had better efficacy in mice.223 2010 has continued to produce animal studies and Cheney 
contributed to this area with a case study of lamotrigine salts and cocrystals where the 
cocrystals decreased the serum concentration in rats.143 Also in 2010 Stanton provides us 
more animal studies with AMG 517 cocrystallized with carboxylic acids and their 
corresponding amides in rats via oral gavage at 100 mg/kg resulting in 2.4 – 7.1 fold 
increase for all cocrystals in plasma AUC over six hours compared to the free base.206 An 
interesting part of this study was the concomitant measurement of former concentration 
as part of their powder dissolution measurements where increases in benzoic acid and 
benzamide concentrations nicely complimented the decrease in the free base, API, 
concentration implying that the cocrystal dissociates over time, Figure 1.12.206 
 
 
 
Figure 1.12: Powder dissolution profiles over 4 hrs for AMG 517 pharmaceutical 
 
cocrystals. AMG 517= triangles, benzoic acid = open squares, benzamide = filled 
squares, cinnamic acid = open circles, cinnamide = filled circles.  
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 Finally in 2010 the indomethacin:saccharin pharmaceutical cocrystal was 
analyzed in dogs at pH 1.2 and 7.4, which ended up being comparable to the marketed 
form.216 These examples provide a solid foundation for pharmaceutical cocrystals as a 
tool to fine tune the physicochemical properties of APIs without making or breaking a 
covalent bonds with the possibility of enhancing the PK performance.  
  
1.5.4 Intellectual Property  
 As mentioned in section 1.5.2 patent activity on pharmaceutical cocrystals began 
to increase after the realization in 2003 that physicochemical properties could be 
modified via cocrystallization and that these new crystalline forms are new compositions 
of matter with unpredictable new physicochemical properties enabling them as patentable 
forms. This new intellectual property caught the attention of the pharmaceutical industry 
very rapidly and caused an increase in patent activity.179-182, 224-225 Pharmaceutical 
cocrystals offer the advantage of life cycle management on old API’s as well as improved 
clinical performance. Similar to salt screening, cocrystal screening has now become 
another tool for preformulation chemists to search for novel crystalline forms with novel 
physicochemical properties expanding the scope of pipeline production. There are two 
examples of how important crystal forms are to intellectual property and while they are 
not cocrystals they still represent the importance of crystalline forms in general to the 
pharmaceutical industry. The first is the case of ranitidine.  
 Ranitidine HCl, marketed as Zantac®, was developed in the 1970’s by Allen and 
Hanburys Ltd. as part of the Glaxo group, now GlaxoSmithKline (GSK), for antagonism 
of the histamine H2 receptor for the treatment of ulcers. The hydrochloride salt was 
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discovered and patented by Glaxo in 1978.226 In 1980 a batch was found to have different 
PXRD and IR data and this new form was called form II227 for which two patents were 
granted in 1985 and 1987. Before expiration of the form I patent generic companies 
attempted to produce form I to be ready to market it by replicating example 32 of the 
form I patent but they claimed this example led to form II and therefore the form II patent 
is invalid but Glaxo wins in litigation proving form I can be made by example 32 and 
claims form II seeds were present in the generic companies attempts.46 The generic 
companies then continue to pursue form I and Glaxo sues, still claiming form II is 
present, but this time they lose, however the litigation took till 1998 allowing Glaxo to 
continue to make money on form I longer than they should have. At that time this was the 
highest grossing API pulling in billions of dollars. 
 The second is the case of ritonavir, an HIV protease inhibitor marketed by Abbott 
Laboratories. In 1996 ritonavir was marketed as Norvir® and was available as an oral 
liquid or a semi-solid capsule. Both of these formulations contained an aqueous ethanolic 
solution because the solid-state form was not bioavailable. During research and 
development only one crystal form was discovered and 240 lots of the capsules were 
made without any problems.54 By the middle of 1998 however, some lots had failed 
dissolution testing due to a new polymorph with very reduced solubility, which was 
characterized and found to be a conformational polymorph.  
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This new, more stable but less soluble, form II of ritonavir then popped up throughout the 
manufacturing process putting a halt to the old formulation. This cost Abbott about $250 
million dollars and lots of bad publicity.228 These examples of crystal form control 
highlight the importance of extensive polymorph screens and, in the case of ritonavir, 
even a liquid formulation needs solid-state form screening in order to avoid potential 
precipitation. 
 
1.6 References Cited 
(1)   Muller-Dethlefs, K.; Hobza, P., Chemical Reviews 2000, 100, 143. 
(2)   van der Waals, D., Die Kontinuitat des gasformigenund flussigen Zustandes. 
Amsterdam, 1881. 
(3)   Margenau, H., Reviews of Modern Physics 1939, 11, 0001. 
(4)   Debye, P., Physikalische Zeitschrift 1920, 21, 178. 
(5)   Keesom, W. H., Physikalische Zeitschrift 1921, 22, 129. 
(6)   Bondi, A., Journal of Physical Chemistry 1964, 68, 441. 
(7)   Elliott, J. R.; Suresh, S. J.; Donohue, M. D., Industrial & Engineering Chemistry 
Research 1990, 29, 1476. 
(8)   Steed, J. W.; Atwood, J. L., Supramolecular Chemistry. John Wiley and Sons: West 
Sussex, United Kingdom, 2009; Vol. 2. 
(9)   Moulton, B.; Zaworotko, M. J., Chemical Reviews 2001, 101, 1629. 
(10)   James, S. L., Chemical Society Reviews 2003, 32, 276. 
(11)   Pauling, L., The Nature of the Chemical Bond. Cornell University Press: Ithaca, 
New York, 1939. 
35 
 
(12)   Desiraju, G. R., Accounts of Chemical Research 2002, 35, 565. 
(13)   Lehn, J. M., Science 1985, 227, 849. 
(14)   Wolf, K. L.; Wolff, R., Angewandte Chemie 1949, 61, 191. 
(15)   Lehn, J. M., Angewandte Chemie-International Edition in English 1988, 27, 89. 
(16)   Fischer, E., Ber. Deutsch. Chem. Ges. 1894, 27. 
(17)   Pedersen, C. J., Journal of the American Chemical Society 1967, 89, 7017. 
(18)   Pedersen, C. J.; Frensdor.Hk, Angewandte Chemie-International Edition 1972, 11, 
16. 
(19)   Cram, D. J., Angewandte Chemie-International Edition in English 1988, 27, 1009. 
(20)   Cram, D. J.; Cram, J. M., Science 1974, 183, 803. 
(21)   Dietrich, B.; Lehn, J. M.; Sauvage, J. P., Tetrahedron Letters 1969, 2885. 
(22)   Graf, E.; Kintzinger, J. P.; Lehn, J. M.; Lemoigne, J., Journal of the American 
Chemical Society 1982, 104, 1672. 
(23)   Cram, D. J., Science 1983, 219, 1177. 
(24)   Watson, J. D.; Crick, F. H. C., Nature 1953, 171, 737. 
(25)   Byrn, S. R.; Pfeiffer, R. R.; Stowell, J. G., Solid-State Chemistry of Drugs. 2nd ed.; 
SSCI, Inc.: West Lafayette, Indiana, 1999. 
(26)   Davey, R.; Garside, J., From Molecules to Crystallizers: An Introduction to 
Crystallization. Oxford University Press: New York, 2000. 
(27)   Steed, J. W., Crystengcomm 2003, 5, 169. 
(28)   Bis, J. A.; Zaworotko, M. J., Crystal Growth & Design 2005, 5, 1169. 
(29)   Aakeroy, C. B.; Fasulo, M. E.; Desper, J., Molecular Pharmaceutics 2007, 4, 317. 
(30)   Childs, S. L.; Stahly, G. P.; Park, A., Molecular Pharmaceutics 2007, 4, 323. 
36 
 
(31)   Desiraju, G. R., Crystengcomm 2003, 5, 466. 
(32)   Dunitz, J. D., Crystengcomm 2003, 5, 506. 
(33)   Trask, A. V., Molecular Pharmaceutics 2007, 4, 301. 
(34)   Zukerman-Schpector, J.; Tiekink, E. R. T., Zeitschrift Fur Kristallographie 2008, 
223, 233. 
(35)   Almarsson, O.; Zaworotko, M. J., Chemical Communications 2004, 1889. 
(36)   Weyna, D. R.; Shattock, T.; Vishweshwar, P.; Zaworotko, M. J., Crystal Growth & 
Design 2009, 9, 1106. 
(37)   Hoogsteen, Acta Cryst 1959, 12, 822. 
(38)   Schmidt, J.; Snipes, J., International Journal of Radiation Biology and Related 
Studies in Physics Chemistry and Medicine 1967, 13, 101. 
(39)   Wöhler, F., Justus Liebigs Ann. Chem. 1844, 51, 153. 
(40)   Vanniekerk, J. N.; Saunder, D. H., Acta Crystallographica 1948, 1, 44. 
(41)   Buck, J. S.; Ide, W. S., Journal of the American Chemical Society 1931, 53, 2784. 
(42)   Anderson, J. S., Nature 1937, 140, 583. 
(43)   Pekker, S.; Kovats, E.; Oszlanyi, G.; Benyei, G.; Klupp, G.; Bortel, G.; Jalsovszky, 
I.; Jakab, E.; Borondics, F.; Kamaras, K.; Bokor, M.; Kriza, G.; Tompa, K.; 
Faigel, G., Nature Materials 2005, 4, 764. 
(44)   Hall, B.; Devlin, J. P., Journal of Physical Chemistry 1967, 71, 465. 
(45)   Ling, A. R.; Baker, J. L., J. Chem. Soc. 1893, 63, 1314. 
(46)   Bernstein, J., Polymorphism in Molecular Crystals. Clarendon Press: Oxford, 2002. 
(47)   McCrone, W. C.; Haleblian, J., Journal of Pharmaceutical Sciences 1969, 58, 911. 
37 
 
(48)   Cheney, M. L.; Weyna, D. R.; Shan, N.; Hanna, M.; Wojtas, L.; Zaworotko, M. J., 
Crystal Growth & Design 2010, 10, 4401. 
(49)   Chen, S.; Guzei, I. A.; Yu, L., Journal of the American Chemical Society 2005, 
127, 9881. 
(50)   Vippagunta, S. R.; Brittain, H. G.; Grant, D. J. W., Advanced Drug Delivery 
Reviews 2001, 48, 3. 
(51)   Corradin.P, Chimica & L Industria 1973, 55, 122. 
(52)   Bernstein, J.; Hagler, A. T., Journal of the American Chemical Society 1978, 100, 
673. 
(53)   Brittain, H. G., Polymorphism in Pharmaceutical Solids. Marcel Dekker: New 
York, 1999; Vol. 95. 
(54)   Bauer, J.; Spanton, S.; Henry, R.; Quick, J.; Dziki, W.; Porter, W.; Morris, J., 
Pharmaceutical Research 2001, 18, 859. 
(55)   McMurray, J.; Fay, R. C., Chemistry. 4 ed.; Prentice Hall: Upper Saddle River, 
New Jersey, 2004. 
(56)   Lapidus, S. H.; Stephens, P. W.; Arora, K. K.; Shattock, T. R.; Zaworotko, M. J., 
Crystal Growth & Design 2010, 10, 4630. 
(57)   Braga, D., Chemical Communications 2003, 2751. 
(58)   Desiraju, G. R., Crystal Engineering: The Design of Organic Solids. Elsevier: 
1989. 
(59)   Pepinsky, R., Physical Review 1955, 100, 971. 
(60)   Schmidt, G. M. J., Pure and Applied Chemistry 1971, 27, 647. 
38 
 
(61)   MacGillivray, L. R.; Reid, J. L.; Ripmeester, J. A., Journal of the American 
Chemical Society 2000, 122, 7817. 
(62)   Etter, M. C., Accounts of Chemical Research 1990, 23, 120. 
(63)   Etter, M. C., Journal of Physical Chemistry 1991, 95, 4601. 
(64)   Etter, M. C.; Adsmond, D. A., Journal of the Chemical Society-Chemical 
Communications 1990, 589. 
(65)   Etter, M. C.; Adsmond, D. A.; Britton, D., Acta Crystallographica Section C-
Crystal Structure Communications 1990, 46, 933. 
(66)   Etter, M. C.; Macdonald, J. C.; Bernstein, J., Acta Crystallographica Section B-
Structural Science 1990, 46, 256. 
(67)   Etter, M. C.; Urbanczyklipkowska, Z.; Ziaebrahimi, M.; Panunto, T. W., Journal of 
the American Chemical Society 1990, 112, 8415. 
(68)   VidenovaAdrabinska, V.; Etter, M. C., Journal of Chemical Crystallography 1995, 
25, 823. 
(69)   Desiraju, G. R., Angewandte Chemie-International Edition in English 1995, 34, 
2311. 
(70)   Walsh, R. D. B.; Bradner, M. W.; Fleischman, S.; Morales, L. A.; Moulton, B.; 
Rodriguez-Hornedo, N.; Zaworotko, M. J., Chemical Communications 2003, 186. 
(71)   Lisgarten, J. N.; Palmer, R. A.; Saldanha, J. W., Journal of Crystallographic and 
Spectroscopic Research 1989, 19, 641. 
(72)   Vishweshwar, P.; McMahon, J. A.; Oliveira, M.; Peterson, M. L.; Zaworotko, M. 
J., Journal of the American Chemical Society 2005, 127, 16802. 
39 
 
(73)   Vishweshwar, P.; Beauchamp, D. A.; Zaworotko, M. J., Crystal Growth & Design 
2006, 6, 2429. 
(74)   Leiserowitz.L; Schmidt, G. M. J., Journal of the Chemical Society a -Inorganic 
Physical Theoretical 1969, 2372. 
(75)   Etter, M. C., Journal of the American Chemical Society 1982, 104, 1095. 
(76)   Leiserowitz, L., Acta Crystallographica Section B-Structural Science 1976, 32, 
775. 
(77)   Beckman, Z. Physikal. Chem. 1897, 22, 610. 
(78)   Wall, F. T.; Banes, F. W., Journal of the American Chemical Society 1945, 67, 898. 
(79)   Wall, F. T.; Rouse, P. E., Journal of the American Chemical Society 1941, 63, 
3002. 
(80)   Leiserowitz, L.; Nader, F., Acta Crystallographica Section B-Structural Science 
1977, 33, 2719. 
(81)   Fleischman, S. G.; Kuduva, S. S.; McMahon, J. A.; Moulton, B.; Walsh, R. D. B.; 
Rodriguez-Hornedo, N.; Zaworotko, M. J., Crystal Growth & Design 2003, 3, 
909. 
(82)   McMahon, J. A.; Bis, J. A.; Vishweshwar, P.; Shattock, T. R.; McLaughlin, O. L.; 
Zaworotko, M. J., Zeitschrift Fur Kristallographie 2005, 220, 340. 
(83)   Aakeroy, C. B.; Beatty, A. M.; Helfrich, B. A., Journal of the American Chemical 
Society 2002, 124, 14425. 
(84)   Bhogala, B. R.; Vishweshwar, P.; Nangia, A., Crystal Growth & Design 2002, 2, 
325. 
(85)   Bond, A. D., Chemical Communications 2003, 250. 
40 
 
(86)   Vishweshwar, P.; Nangia, A.; Lynch, V. M., Journal of Organic Chemistry 2002, 
67, 556. 
(87)   Dey, A.; Kirchner, M. T.; Vangala, V. R.; Desiraju, G. R.; Mondal, R.; Howard, J. 
A. K., Journal of the American Chemical Society 2005, 127, 10545. 
(88)   Hanessian, S.; Saladino, R.; Margarita, R.; Simard, M., Chemistry-a European 
Journal 1999, 5, 2169. 
(89)   Mondal, R.; Howard, J. A. K.; Banerjee, R.; Desiraju, G. R., Crystal Growth & 
Design 2006, 6, 2507. 
(90)   Vangala, V. R.; Mondal, R.; Broder, C. K.; Howard, J. A. K.; Desiraju, G. R., 
Crystal Growth & Design 2005, 5, 99. 
(91)   MacGillivray, L. R.; Atwood, J. L., Journal of Solid State Chemistry 2000, 152, 
199. 
(92)   Papaefstathiou, G. S.; MacGillivray, L. R., Organic Letters 2001, 3, 3835. 
(93)   Vishweshwar, P.; Nangia, A.; Lynch, V. M., Crystengcomm 2003, 164. 
(94)   Aakeroy, C. B., Acta Crystallographica Section B-Structural Science 1997, 53, 
569. 
(95)   Aakeroy, C. B.; Beatty, A. M., Australian Journal of Chemistry 2001, 54, 409. 
(96)   Aakeroy, C. B.; Beatty, A. M.; Helfrich, B. A., Angewandte Chemie-International 
Edition 2001, 40, 3240. 
(97)   Aakeroy, C. B.; Seddon, K. R., Chemical Society Reviews 1993, 22, 397. 
(98)   Aakeroy, C. B.; Desper, J.; Smith, M. M., Chemical Communications 2007, 3936. 
(99)   Aakeroy, C. B.; Salmon, D. J., Crystengcomm 2005, 7, 439. 
41 
 
(100)   Bis, J. A.; Vishweshwar, P.; Weyna, D.; Zaworotko, M. J., Molecular 
Pharmaceutics 2007, 4, 401. 
(101)   Shattock, T. R.; Arora, K. K.; Vishweshwar, P.; Zaworotko, M. J., Crystal Growth 
& Design 2008, 8, 4533. 
(102)   Kavuru, P.; Aboarayes, D.; Arora, K. K.; Clarke, H. D.; Kennedy, A.; Marshall, 
L.; Ong, T. T.; Perman, J.; Pujari, T.; Wojtas, L.; Zaworotko, M. J., Crystal 
Growth & Design 2010, 10, 3568. 
(103)   Aakeroy, C. B.; Hughes, D. P.; Nieuwenhuyzen, M., Journal of the American 
Chemical Society 1996, 118, 10134. 
(104)   Gilli, P.; Bertolasi, V.; Ferretti, V.; Gilli, G., Journal of the American Chemical 
Society 1994, 116, 909. 
(105)   Russell, V. A.; Etter, M. C.; Ward, M. D., Chemistry of Materials 1994, 6, 1206. 
(106)   Ward, M. D., Chemical Communications 2005, 5838. 
(107)   Sudhakar, V.; Bhat, T. N.; Vijayan, M., Acta Crystallographica Section B-
Structural Science 1980, 36, 125. 
(108)   Chen, A. M.; Ellison, M. E.; Peresypkin, A.; Wenslow, R. M.; Variankaval, N.; 
Savarin, C. G.; Natishan, T. K.; Mathre, D. J.; Dormer, P. G.; Euler, D. H.; Ball, 
R. G.; Ye, Z. X.; Wang, Y. L.; Santos, I., Chemical Communications 2007, 419. 
(109)   Childs, S. L.; Chyall, L. J.; Dunlap, J. T.; Smolenskaya, V. N.; Stahly, B. C.; 
Stahly, G. P., Journal of the American Chemical Society 2004, 126, 13335. 
(110)   Cincic, D.; Friscic, T.; Jones, W., Journal of the American Chemical Society 
2008, 130, 7524. 
42 
 
(111)   Aakeroy, C. B.; Beatty, A. M.; Lorimer, K. R., Structural Chemistry 1999, 10, 
229. 
(112)   Aakeroy, C. B.; Schultheiss, N.; Desper, J.; Moore, C., Crystengcomm 2007, 9, 
420. 
(113)   Banerjee, R.; Desiraju, G. R.; Mondal, R.; Howard, J. A. K., Chemistry-a 
European Journal 2004, 10, 3373. 
(114)   Metrangolo, P.; Meyer, F.; Pilati, T.; Resnati, G.; Terraneo, G., Angewandte 
Chemie-International Edition 2008, 47, 6114. 
(115)   Metrangolo, P.; Neukirch, H.; Pilati, T.; Resnati, G., Accounts of Chemical 
Research 2005, 38, 386. 
(116)   Thakur, T. S.; Kirchner, M. T.; Blaser, D.; Boese, R.; Desiraju, G. R., 
Crystengcomm 2010, 12, 2079. 
(117)   Allen, F. H., Acta Crystallographica Section B-Structural Science 2002, 58, 380. 
(118)   Allen, F. H.; Hoy, V. J., International Tables for Crystallography. 2006; Vol. F. 
(119)   Allen, F. H.; Motherwell, W. D. S., Acta Crystallographica Section B-Structural 
Science 2002, 58, 407. 
(120)   Blatov, V. A.; Carlucci, L.; Ciani, G.; Proserpio, D. M., Crystengcomm 2004, 6, 
377. 
(121)   Infantes, L.; Motherwell, W. D. S., Zeitschrift Fur Kristallographie 2005, 220, 
333. 
(122)   Oswald, I. D. H.; Motherwell, W. D. S.; Parsons, S.; Pidcock, E.; Pulham, C. R., 
Crystallography Reviews 2004, 10, 57. 
43 
 
(123)   Clarke, H. D.; Arora, K. K.; Bass, H.; Kavuru, P.; Ong, T. T.; Pujari, T.; Wojtas, 
L.; Zaworotko, M. J., Crystal Growth & Design 2010, 10, 2152. 
(124)   Russell, V. A.; Evans, C. C.; Li, W. J.; Ward, M. D., Science 1997, 276, 575. 
(125)   Zaworotko, M., Journal of Pharmacy and Pharmacology 2006, 58, A91. 
(126)   Taylor, L. D.; Warner, J. C. US 5,338,644A Process and composition for use in 
photographic materials containing hydroquihones. 1994. 
(127)   Maddox, J., Nature 1988, 335, 201. 
(128)   Lommerse, J. P. M.; Motherwell, W. D. S.; Ammon, H. L.; Dunitz, J. D.; 
Gavezzotti, A.; Hofmann, D. W. M.; Leusen, F. J. J.; Mooij, W. T. M.; Price, S. 
L.; Schweizer, B.; Schmidt, M. U.; van Eijck, B. P.; Verwer, P.; Williams, D. E., 
Acta Crystallographica Section B-Structural Science 2000, 56, 697. 
(129)   Dunitz, J. D., Chemical Communications 2003, 545. 
(130)   Ouvrard, C.; Price, S. L., Crystal Growth & Design 2004, 4, 1119. 
(131)   Price, S. L., Advanced Drug Delivery Reviews 2004, 56, 301. 
(132)   Price, S. L., Crystengcomm 2004, 6, 344. 
(133)   Thakur, T. S.; Desiraju, G. R., Crystal Growth & Design 2008, 8, 4031. 
(134)   Day, G. M.; Cooper, T. G.; Cruz-Cabeza, A. J.; Hejczyk, K. E.; Ammon, H. L.; 
Boerrigter, S. X. M.; Tan, J. S.; Della Valle, R. G.; Venuti, E.; Jose, J.; Gadre, S. 
R.; Desiraju, G. R.; Thakur, T. S.; van Eijck, B. P.; Facelli, J. C.; Bazterra, V. E.; 
Ferraro, M. B.; Hofmann, D. W. M.; Neumann, M. A.; Leusen, F. J. J.; Kendrick, 
J.; Price, S. L.; Misquitta, A. J.; Karamertzanis, P. G.; Welch, G. W. A.; Scheraga, 
H. A.; Arnautova, Y. A.; Schmidt, M. U.; van de Streek, J.; Wolf, A. K.; 
44 
 
Schweizer, B., Acta Crystallographica Section B-Structural Science 2009, 65, 
107. 
(135)   Price, S. L., Accounts of Chemical Research 2009, 42, 117. 
(136)   Motherwell, W. D. S.; Ammon, H. L.; Dunitz, J. D.; Dzyabchenko, A.; Erk, P.; 
Gavezzotti, A.; Hofmann, D. W. M.; Leusen, F. J. J.; Lommerse, J. P. M.; Mooij, 
W. T. M.; Price, S. L.; Scheraga, H.; Schweizer, B.; Schmidt, M. U.; van Eijck, B. 
P.; Verwer, P.; Williams, D. E., Acta Crystallographica Section B-Structural 
Science 2002, 58, 647. 
(137)   Day, G. M.; Motherwell, W. D. S.; Ammon, H. L.; Boerrigter, S. X. M.; Della 
Valle, R. G.; Venuti, E.; Dzyabchenko, A.; Dunitz, J. D.; Schweizer, B.; van 
Eijck, B. P.; Erk, P.; Facelli, J. C.; Bazterra, V. E.; Ferraro, M. B.; Hofmann, D. 
W. M.; Leusen, F. J. J.; Liang, C.; Pantelides, C. C.; Karamertzanis, P. G.; Price, 
S. L.; Lewis, T. C.; Nowell, H.; Torrisi, A.; Scheraga, H. A.; Arnautova, Y. A.; 
Schmidt, M. U.; Verwer, P., Acta Crystallographica Section B-Structural Science 
2005, 61, 511. 
(138)   Shan, N.; Zaworotko, M. J., Drug Discovery Today 2008, 13, 440. 
(139)   Trask, A. V.; Jones, W., Crystal engineering of organic cocrystals by the solid-
state grinding approach. In Organic Solid State Reactions, Springer-Verlag 
Berlin: Berlin, 2005; Vol. 254, pp 41. 
(140)   Shan, N.; Toda, F.; Jones, W., Chemical Communications 2002, 2372. 
(141)   Karki, S.; Friscic, T.; Fabian, L.; Laity, P. R.; Day, G. M.; Jones, W., Advanced 
Materials 2009, 21, 3905. 
45 
 
(142)   Dhumal, R. S.; Kelly, A. L.; York, P.; Coates, P. D.; Paradkar, A., 
Pharmaceutical Research 2010, 27, 2725. 
(143)   Cheney, M. L.; Shan, N.; Healey, E. R.; Hanna, M.; Wojtas, L.; Zaworotko, M. J.; 
Sava, V.; Song, S. J.; Sanchez-Ramos, J. R., Crystal Growth & Design 2010, 10, 
394. 
(144)   Friscic, T.; Childs, S. L.; Rizvi, S. A. A.; Jones, W., Crystengcomm 2009, 11, 418. 
(145)   Rodriguez-Hornedo, N.; Nehru, S. J.; Seefeldt, K. F.; Pagan-Torres, Y.; 
Falkiewicz, C. J., Molecular Pharmaceutics 2006, 3, 362. 
(146)   Padrela, L.; Rodrigues, M. A.; Velaga, S. P.; Fernandes, A. C.; Matos, H. A.; de 
Azevedo, E. G., Journal of Supercritical Fluids 2010, 53, 156. 
(147)   Padrela, L.; Rodrigues, M. A.; Velaga, S. R.; Matos, H. A.; de Azevedo, E. G., 
European Journal of Pharmaceutical Sciences 2009, 38, 9. 
(148)   Trask, A. V.; van de Streek, J.; Motherwell, W. D. S.; Jones, W., Crystal Growth 
& Design 2005, 5, 2233. 
(149)   Rather, B.; Zaworotko, M. J., Chemical Communications 2003, 830. 
(150)   Proce'de' de pre'paration de de'rive's de combinasions oxy- et aminopyridques. FR 
769586, 1934. 
(151)   Kim, S. H.; Rich, A., Proceedings of the National Academy of Sciences of the 
United States of America 1968, 60, 402. 
(152)   Kiryu, S., Journal of Pharmaceutical Sciences 1971, 60, 699. 
(153)   Voet, D., Journal of the American Chemical Society 1972, 94, 8213. 
(154)   Hsu, I. N.; Craven, B. M., Acta Crystallographica Section B-Structural Science 
1974, B 30, 843. 
46 
 
(155)   Shefter, E., Journal of Pharmaceutical Sciences 1969, 58, 710. 
(156)   Shefter, E.; Sackman, P., Journal of Pharmaceutical Sciences 1971, 60, 282. 
(157)   Giordano, F.; Bettinetti, G. P.; Lamanna, A.; Ferloni, P., Farmaco-Edizione 
Scientifica 1977, 32, 889. 
(158)   Nakao, S.; Fujii, S.; Sakaki, T.; Tomita, K. I., Acta Crystallographica Section B-
Structural Science 1977, 33, 1373. 
(159)   Aoki, K.; Ichikawa, T.; Koinuma, Y.; Iitaka, Y., Acta Crystallographica Section 
B-Structural Science 1978, 34, 2333. 
(160)   Giuseppetti, G.; Tadini, C.; Bettinetti, G. P.; Giordano, F.; Lamanna, A., 
Farmaco-Edizione Scientifica 1980, 35, 138. 
(161)   Shimizu, N.; Nishigaki, S.; Nakai, Y.; Osaki, K., Acta Crystallographica Section 
B-Structural Science 1982, 38, 2309. 
(162)   Wiedenfeld, H.; Knoch, F., Archiv Der Pharmazie 1986, 319, 654. 
(163)   Zerkowski, J. A.; Seto, C. T.; Wierda, D. A.; Whitesides, G. M., Journal of the 
American Chemical Society 1990, 112, 9025. 
(164)   Caira, M. R., Journal of Crystallographic and Spectroscopic Research 1991, 21, 
641. 
(165)   Caira, M. R., Journal of Crystallographic and Spectroscopic Research 1992, 22, 
193. 
(166)   Zerkowski, J. A.; Seto, C. T.; Whitesides, G. M., Journal of the American 
Chemical Society 1992, 114, 5473. 
(167)   He, L.; Liu, Y.; Lin, M.; Awika, J.; Ledoux, D.; Li, H.; Mustapha, A., Sensing and 
Instrumentation for Food Quality and Safety 2008, 2, 66. 
47 
 
(168)   Scott McDonald, "Nearly 53,000 Chinese children sick from milk". Associated 
Press 2008. 
(169)   Jane Macartney. "China baby milk scandal spreads as sick toll rises to 13,000". 
The Times (London). 2008  
(170)   Meade, E. M. Sodium Hydrogen Divalproate Oligomer. US 5,212,326, 1993. 
(171)   Zerkowski, J. A.; Mathias, J. P.; Whitesides, G. M., Journal of the American 
Chemical Society 1994, 116, 4305. 
(172)   Zerkowski, J. A.; Whitesides, G. M., Journal of the American Chemical Society 
1994, 116, 4298. 
(173)   Koshima, H.; Ding, K. L.; Chisaka, Y.; Matsuura, T., Tetrahedron-Asymmetry 
1995, 6, 101. 
(174)   AMOS, J. G.; INDELICATO, J. M.; PASINI, C. E.; REUTZEL, S. M. Bicyclic 
beta-lactam/paraben complexes. EP0637587 B1 1997. 
(175)   Zerkowski, J. A.; MacDonald, J. C.; Whitesides, G. M., Chemistry of Materials 
1997, 9, 1933. 
(176)   BAJAJ, V.; MADAN, A. K. A process for preparation of urea complexes of 
vitamin e and its esters  IN182620 A1, 1999. 
(177)   Lynch, D. E.; Sandhu, P.; Parsons, S., Australian Journal of Chemistry 2000, 53, 
383. 
(178)   Vishweshwar, P.; Thaimattam, R.; Jaskolski, M.; Desiraju, G. R., Chemical 
Communications 2002, 1830. 
48 
 
(179)   Remenar, J.; Macphee, M.; Peterson, M. L.; Morissette, S. L.; Almarsson, ö. 
Novel Conazole Crystalline Forms and Related Processes, Pharmaceutical 
Compositions and Methods WO 2003101392, 2003. 
(180)   Almarsson, Ö.; Hickey, M. B.; Peterson, M.; Zaworotko, M. J.; Moulton, B.; 
Rodriguez-Hornedo, N. Pharmaceutical Cocrystal Compositions of Drugs such as 
Carbamazepine, Celecoxib, Olanzapine, Itraconazole, Topirimate, Modafinil, 5-
Fluorouracil, Hydrochlorothiazide, Acetaminophen, Aspirin, Flurbiprofen, 
Phenytoin, an Ibuprofen WO2004078161, 2004. 
(181)   Childs, S. L. Novel Cocrystallization. WO2004064762, 2004. 
(182)   Hickey, M. B.; Remenar, J. Novel Olanzapine Forms and Related Methods of 
Treatment WO2004089313, 2004. 
(183)   Jayasankar, A.; Somwangthanaroj, A.; Shao, Z. J.; Rodriguez-Hornedo, N., 
Pharmaceutical Research 2006, 23, 2381. 
(184)   Nehm, S. J.; Rodriguez-Spong, B.; Rodriguez-Hornedo, N., Crystal Growth & 
Design 2006, 6, 592. 
(185)   Jayasankar, A.; Good, D. J.; Rodriguez-Hornedo, N., Molecular Pharmaceutics 
2007, 4, 360. 
(186)   Seefeldt, K.; Miller, J.; Alvarez-Nunez, F.; Rodriguez-Hornedo, N., Journal of 
Pharmaceutical Sciences 2007, 96, 1147. 
(187)   Childs, S. L.; Wood, P. A.; Rodriguez-Hornedo, N.; Reddy, L. S.; Hardcastle, K. 
I., Crystal Growth & Design 2009, 9, 1869. 
(188)   Good, D. J.; Rodriguez-Hornedo, N., Crystal Growth & Design 2009, 9, 2252. 
49 
 
(189)   Valder, C.; Merrifield, D., Pharmaceutical Technology, SmithKline Beechum RD 
News 1996. 
(190)   Byrn, S. R.; Pfeiffer, R. R.; Stephenson, G.; Grant, D. J. W.; Gleason, W. B., 
Chemistry of Materials 1994, 6, 1148. 
(191)   Berge, S. M.; Bighley, L. D.; Monkhouse, D. C., Journal of Pharmaceutical 
Sciences 1977, 66, 1. 
(192)   Haleblian, J. K., Journal of Pharmaceutical Sciences 1975, 64, 1269. 
(193)   Noyes, A.; Whitney, W., Journal of the American Chemical Society 1897, 19, 
930. 
(194)   Bruner, L.; Tolloczko, S., Zeitschrift Fur Physikalische Chemie--Stochiometrie 
Und Verwandtschaftslehre 1900, 35, 283. 
(195)   Brunner, E., Zeitschrift Fur Physikalische Chemie--Stochiometrie Und 
Verwandtschaftslehre 1904, 47, 56. 
(196)   Nernst, N., Zeitschrift Fur Physikalische Chemie--Stochiometrie Und 
Verwandtschaftslehre 1904, 47, 52. 
(197)   Dokoumetzidis, A.; Macheras, P., International Journal of Pharmaceutics 2006, 
321, 1. 
(198)   Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R., Pharmaceutical 
Research 1995, 12, 413. 
(199)   Zaki, N. M.; Artursson, P.; Bergstrom, C. A. S., Molecular Pharmaceutics 2010, 
7, 1478. 
50 
 
(200)   Remenar, J. F.; Morissette, S. L.; Peterson, M. L.; Moulton, B.; MacPhee, J. M.; 
Guzman, H. R.; Almarsson, O., Journal of the American Chemical Society 2003, 
125, 8456. 
(201)   McNamara, D. P.; Childs, S. L.; Giordano, J.; Iarriccio, A.; Cassidy, J.; Shet, M. 
S.; Mannion, R.; O'Donnell, E.; Park, A., Pharmaceutical Research 2006, 23, 
1888. 
(202)   Variankaval, N.; Wenslow, R.; Murry, J.; Hartman, R.; Helmy, R.; Kwong, E.; 
Clas, S. D.; Dalton, C.; Santos, I., Crystal Growth & Design 2006, 6, 690. 
(203)   Hickey, M. B.; Peterson, M. L.; Scoppettuolo, L. A.; Morrisette, S. L.; Vetter, A.; 
Guzman, H.; Remenar, J. F.; Zhang, Z.; Tawa, M. D.; Haley, S.; Zaworotko, M. 
J.; Almarsson, O., European Journal of Pharmaceutics and Biopharmaceutics 
2007, 67, 112. 
(204)   Annette Bak; Gore, A.; Yanez, E.; Stanton, M.; Tufekcic, S.; Syed, R.; Akrami, 
A.; Rose, M.; Surapaneni, S.; Bostick, T.; King, A.; Neervannan, S.; Ostovic, D.; 
Koparkar, A., Journal of Pharmaceutical Sciences 2008, 97, 3942. 
(205)   Cheney, M. L.; Weyna, D. R.; Shan, N.; Hanna, M.; Wojtas, L.; Zaworotko, M. J., 
Journal of Pharmaceutical Sciences 2010, Published Online DOI: 
10.1002/jps.22434. 
(206)   Stanton, M. K.; Kelly, R. C.; Colletti, A.; Kiang, Y. H.; Langley, M.; Munson, E. 
J.; Peterson, M. L.; Roberts, J.; Wells, M., Journal of Pharmaceutical Sciences 
2010, 99, 3769. 
(207)   Basavoju, S.; Bostrom, D.; Velaga, S. P., Crystal Growth & Design 2006, 6, 2699. 
51 
 
(208)   Remenar, J. F.; Peterson, M. L.; Stephens, P. W.; Zhang, Z.; Zimenkov, Y.; 
Hickey, M. B., Molecular Pharmaceutics 2007, 4, 386. 
(209)   Zegarac, M.; Mestrovic, E.; Dumbovic, A.; Devcic, M.; Tudja, P. 
Pharmaceutically Acceptable Co-Crystalline Forms of Sildenafil. WO 
2007/080362 A1, 2007. 
(210)   Shiraki, K.; Takata, N.; Takano, R.; Hayashi, Y.; Terada, K., Pharmaceutical 
Research 2008, 25, 2581. 
(211)   Stanton, M. K.; Bak, A., Crystal Growth & Design 2008, 8, 3856. 
(212)   Stanton, M. K.; Tufekcic, S.; Morgan, C.; Bak, A., Crystal Growth & Design 
2009, 9, 1344. 
(213)   Lee, H. G.; Zhang, G. G. Z.; Flanagan, D. R., Journal of Pharmaceutical Sciences 
2010, n/a. 
(214)   Takata, N.; Takano, R.; Uekusa, H.; Hayashi, Y.; Terada, K., Crystal Growth & 
Design 2010, 10, 2116. 
(215)   Basavoju, S.; Bostrom, D.; Velaga, S. P., Pharmaceutical Research 2008, 25, 530. 
(216)   Jung, M. S.; Kim, J. S.; Kim, M. S.; Alhalaweh, A.; Cho, W.; Hwang, S. J.; 
Velaga, S. P., Journal of Pharmacy and Pharmacology 2010, 62, 1560. 
(217)   Trask, A. V.; Motherwell, W. D. S.; Jones, W., International Journal of 
Pharmaceutics 2006, 320, 114. 
(218)   Friscic, T.; Fabian, L.; Burley, J. C.; Reid, D. G.; Duer, M. J.; Jones, W., 
Chemical Communications 2008, 1644. 
(219)   Rahman, Z.; Samy, R.; Sayeed, V. A.; Khan, M. A., Pharmaceutical Development 
and Technology 0, 1. 
52 
 
53 
 
(220)   Peterson, M.; Bourghol Hickey, M.; Oliveira, M.; Almarsson, O.; Remenar, J. 
Modafinil compositions. US 2005267209 A1, 2005. 
(221)   Remenar, J.; MacPhee, M.; Peterson, M.; Morissette, S. L.; Almarsson, O. Novel 
Crystalline Forms of Conazoles and Methods of Making and Using the Same. 
WO/2005/092884, 2005. 
(222)   E. Dova; J. M.  Mazurek; Anker, J. Tenofovir disoproxil hemi-fumaric acid co-
crystal.  WO/2008/143500 2008. 
(223)   Imamura, M. Cocrystal of C-Glycoside Derivative and L-Proline. WO 
2007/114475 A1, 2007. 
(224)   Wang, S.; Chen, J. Gossypol Co-crystals and the use thereof. WO2005094804. 
(225)   Childs, S. L. Metronidazole cocrystals and imipramine cocrystals. WO  
2007067727  A2  2007. 
(226)   Price, B. J.; Clitherow, J. W.; Bradshaw, J. W. Aminoalkyl furan derivatives. US 
4128568, 1978. 
(227)   Crookes, D. Amino Alkyl Furan Derivative. US 4521431, 1985. 
(228)   Chemical and Engineering News Vol 85 No.25, 2007. 
 
 
  
 
Chapter 2: Mechanochemistry: Solvent Drop Grinding vs. Solution Evaporation for 
the Synthesis of Pharmaceutical Cocrystals Involving Carbamazepine 
 
2.1 Background 
 Carbamazepine (CBZ) is an API with the brand name Tegretol® that is 
used mainly as an anticonvulsant but also as an analgesic and is known as 5H-
dibenzo[b,f]azepine-5-carboxamide. Oral dosage forms consist of tablets or a suspension 
with eighty percent bioavailability despite its low aqueous solubility, however, the 
absorption is slow in humans with a variable half life of twenty five to sixty five hours. 
CBZ represents a microcosm of the challenges and opportunities related to crystal forms 
of APIs since it exhibits polymorphism1 to the extent of eight different polymorphs2-10 
and readily forms a less soluble dihydrate when exposed to moisture.11 The amide 
functionality predisposes this molecule to various H-bonding possibilities. Therefore, it 
should not be surprising that CBZ was an early candidate for cocrystallization studies12-13 
and it is one of the few APIs for which there is published data concerning bioavailability 
of a cocrystal, the 1:1 cocrystal of CBZ and saccharin. This cocrystal does not form a 
hydrate and it exhibits improved bioavailability in dogs when compared to Tegretol® 
tablets, Figure 1.11.14 In fact, it has been proposed that the CBZ:Nicotinamide cocrystal 
exhibits a 152-fold increase in aqueous solubility compared to the dihydrate.15  
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Zaworotko12, 16 and others17 have reported that CBZ forms supramolecular 
adducts with a wide range of complementary cocrystal formers and a recent report 
addressed the preparation of CBZ cocrystals through four different methodologies, 
including solvent drop grinding (SDG).17  The research herein addresses SDG as a 
methodology for the reproduction of cocrystals with CBZ that have been previously 
reported via solution crystallization using and a wide range of organic coformers and 
solvents with varying functionalities.  
Mechanochemistry in its earliest incarnation, grinding of solids, is a technique 
that dates back thousands of years in that tribal medicine utilized something similar to a 
mortar and pestle to process medicinally beneficial plants18 and even today a mortar and 
pestle symbolizes pharmacies and schools of pharmacy. To the best of my knowledge, 
the first report of mechanochemistry in the scientific literature of appeared over 160 years 
ago in 1844 when Wöhler prepared the 1:1 quinone•hydroquinone cocrystal by 
“kugelchen”.19 In 1893 cocrystals of charge transfer complexes were studied and they 
were also prepared via grinding of solids.20 Today solid state grinding represents an 
attractive alternative to solution processes because it is an inherently “Green” approach to 
synthetic chemistry in that it offers a facile and low or no waste methodology for 
discovery or processing of new or existing compounds. Recent interest in grinding and 
cocrystals can be traced to the 1980’s, when Etter et al. demonstrated that dry grinding, 
also referred to as neat grinding, represents a viable methodology to prepare cocrystals 
of, for example. methyladenine and methylthymine.21-29 An important refinement to 
grinding came when a small but controlled amount of solvent was added during the 
grinding process. SDG was reported by Shan et al. in 2002 and it became evident that the 
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kinetics of cocrystal formation can be significantly enhanced through SDG.30 SDG can 
offer other advantages over solution crystallization since dissolution of both cocrystal 
formers is not required, solvent interactions that might interfere with solute-solute 
interactions are more limited and we are taken to a region of the ternary phase diagram 
that might favor cocrystals over starting materials. Indeed, in certain cases SDG can 
produce cocrystals that are not readily obtainable through solution crystallization and 
SDG can be employed for control over polymorphism in caffeine:glutaric acid 
cocrystals.31-35  Two concomitant polymorphs of the caffeine:glutaric acid cocrystal result 
from solution but SDG with a non-polar solvent afforded only form I whereas a polar 
solvent afforded only form II.36 SDG has been used in other situations to control 
polymorphism.37-38 Whereas there are numerous examples of cocrystals made by SDG 
that have also been grown from solution and characterized by single crystal X-ray 
diffraction, a direct comparison of the efficacy of SDG vs. solution crystallization over a 
wide range of cocrystal formers has not been systematically studied.39-42   This is 
addressed herein through studying cocrystals with the range of supramolecular synthons43 
involving CBZ, Figures 2.1 and 2.2.  
 
 
Figure 2.1: Chemical diagram of CBZ. 
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 Figure 2.2: Chemical diagrams of the cocrystal formers employed. 
 
2.2 Experimental Details 
2.2.1 Materials 
 Reagents were obtained from commercial sources and used as received. Solvents 
were obtained from commercial sources and distilled before use.  
2.2.2 Methods 
 Cocrystals were characterized by infrared spectroscopy (IR), X-ray powder 
diffraction (PXRD), and single crystal X-ray analysis where applicable. IR data was 
collected using a Nicolet Avatar 320 FTIR instrument. PXRD data was collected using a 
Bruker AXS D8 discover X-ray diffractometer equipped with GADDS™ (General Area 
Diffraction Detection System), a Bruker AXS HI-STAR area detector at a distance of 
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15.05 cm as per system calibration, a copper source, an automated x-y-z stage, and a 0.5 
mm collimator. Data were collected over a 3.0-40.0 2θ range at a step size of 0.05 2θ.  
SDG: Cocrystal formers were subjected to grinding with an agate mortar and pestle 
for 4 minutes and thereafter characterized by IR and PXRD. In the event that partial 
conversion was achieved a ball mill, SPEX 8000M Mixer/Mill, was used for 2 
increments of 10 minutes with addition of solvent prior to each increment. The same 
stoichiometric ratios that the cocrystals exhibited after solution crystallization were used 
for grinding unless otherwise specified.  The volumes of solvents used during SDG were  
are follows: methanol (MeOH) 20 μL, ethylacetate (EtOAc) 20 μL, dimethylsulfoxide 
(DMSO) 4 μL, water 5 μL, toluene (Tol) 20 μL, cyclohexane (Cychex) 20 μL, 
chloroform 20 μL, dimethylformamide (DMF) 4 μL. Each solvent was used for each 
cocrystal experiment. 
  
Experimental details for each of the single crystal crystallizations have been 
previously published12, 14, 16-17 and the SDG experiments were conducted as described 
earlier. The following cocrystals were studied in terms of SDG: 2:1 cocrystal of CBZ and 
4,4’-bipyridine, 1; hydrate of the 1:1 cocrystal of CBZ and 4-aminobenzoic Acid, 2; 1:1 
cocrystal of CBZ and 2,6-pyridinedicarboxylic Acid, 3; 2:1 cocrystal of CBZ and 
benzoquinone, 4; 2:1 cocrystal of CBZ  and terephthalaldehyde, 5; 1:1 cocrystal of CBZ 
and saccharin, 6; 1:1 cocrystal of CBZ and nicotinamide, 7; 1:1 cocrystal of CBZ and 
aspirin, 8. 
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2.3 Results and Discussion 
2.3.1 Reproducibility  
The reliability of SDG to reproduce cocrystals of CBZ that were first prepared by 
slow evaporation was systematically analyzed. Cocrystal formers contained a wide range 
of functional groups which seemed to have no effect on reproducibility. Cocrystals 1-8 
were all reproduced with at least one solvent, Table 2.1.  The 100% rate of success for 
producing cocrystals obtained by solution further confirms the reliability of SDG for 
reproducing a specific form in a controlled fashion with little waste although it remains to 
be seen if SDG and slurrying complement one another. Indeed, a recent study of slurrying 
using ethanol effected polymorphic transformation of the CBZ:isonicotinamide 
cocrystal.44 Experimental and calculated PXRD patterns and IR spectra for 1-8 are 
presented in Appendix 1. 
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9Nicotinamide
1:1                             7
Toluene EtOAcCHCl3 MeOH Cyclohex
Aspirin
1:1                             8
Saccharin
1:1                             6
Terephthalaldehyde
1:2                             5
Benzoquinone
1:2                             4
2,6 pyr dicarb
1:1                             3
HydHyd4-Aminobenzoic acid 
1:2                             2
4,4’ Bipy 1
1:2
DMSODMFWaterCocrystal Former
(Former:Cbz)
*
1
2
3
4
5
6
7
8  
 
Table 2.1: Summary of SDG results for Cbz: Red = starting materials, Green = 
cocrystal formed, and Hyd = hydrate.  
* Indicates Unconverted Starting Materials by Powder X-Ray Diffraction. 
  
2.3.2 Solvent Choice 
 Solvents with a range of polarity from non-polar to polar extremes were 
employed. Organic solvents like Cychex and Tol represent the non-polar side while water 
and DMSO represent the polar side. The middle of the range was covered with solvents 
like MeOH and EtOAc. The solvents used for single crystal growth were not always used 
in this screen however that could be useful in further studies. In the cases where that 
solvent was used the results were a positive match. DMF and DMSO appear particularly 
well suited for SDG.  Given that DMF is slightly less prone to solvate formation when 
compared with DMSO45, it would probably be the solvent of choice if only one SDG 
experiment were to be conducted. 
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However, in the case of 8 only DMSO reproduced the cocrystal form obtained from 
solution. Nevertheless, it is clear that there is an underlying trend: the more soluble the 
API and the cocrystal formers are in the solvent used for SDG, the more likely it is that 
the cocrystal will be produced. 
2.3.3 Utility as a Screening Technique 
This set of SDG experiments involved more than one supramolecular synthon and 
is perhaps more representative of an industrial situation for which crystal form screening 
would probably be conducted with multiple cocrystal formers and solvents. 
Our results complement those of Childs et al.,17 who utilized SDG, evaporation, Sonic 
SlurryTM, and “reaction crystallization” to screen for novel forms of CBZ with 
pharmaceutically accepted carboxylic acids while simultaneously screening for 
polymorphic behavior. Using sonication for cocrystal formation is a relatively recent 
technique which was introduced into the literature by Bucar et al.46 While SDG can be 
used for polymorph screening, other techniques have also been employed: supercritical 
fluid,47 reaction crystallization,17 and Sonic SlurryTM.17   
 
2.4 Conclusions 
 SDG is indeed a viable technique to generate cocrystals since all 8 cocrystals that 
were prepared from solution were reproduced, often times with multiple solvents. 
Alternative methodologies which are also solvent based include crystallizations at high 
pressure48 and slurries49 but, as for slow evaporation, the volume of solvent necessary to 
perform these techniques is usually significant.  Grinding or milling is typically used for 
particle size reduction as a means of improving the dissolution rate of APIs and there also 
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exists a correlation between particle size reduction and bulk properties such as 
flowability, bulk density, mixing ability etc.50 However, cocrystals are new compositions 
of matter and the thermodynamic solubility of the API is therefore not only affected by 
particle size dynamics. Therefore, given that the newest generation of APIs tends to 
exhibit an increasing tendency towards low water solubility, i.e. they are BCS class II 
drugs,51 the generation of pharmaceutical cocrystals could have important implications 
for drug development. That the cocrystals of this study and, by implication, cocrystals in 
general may be synthesized via SDG is therefore relevant to both discovery and 
processing of cocrystals. In addition, SDG provides an eco-friendly alternative to the use 
of relatively large amounts of solvent. In summary, SDG is a broadly useful, inexpensive, 
and “Green” approach to cocrystal formation. 
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Chapter 3: Cocrystallization and Pharmacokinetic Enhancement with Meloxicam 
3.1 Background 
 Traditional routines are resistant to change in the pharmaceutical industry 
but during the 1990’s a major shift revolutionized the in vitro screening process from 
aqueous based manual screening to high throughput screening in the name of efficiency 
and hopes of increased pipeline opportunities. The high throughput process began with 
the utilization of dimethylsulfoxide (DMSO) as a medium which led to numerous hits 
exhibiting very low aqueous solubilities.1 As a result the majority of API’s currently in 
development exhibit aqueous solubilities less than 0.1 mg/mL.2 Meloxicam, 4-hydroxy-2-
methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide, is a 
non-steroidal anti-inflammatory drug (NSAID) originally developed by Boehringer 
Ingleheim in 2000. It is used for the following indications; rheumatoid and osteoarthritis,3 
postoperative pain4-5 and fever.6 Oral doses comes as 7.5 or 15 mg tablets or a 7.5mg/mL 
suspension (no greater than 15 mg per day). It exists as a yellow solid that is practically 
insoluble in water7 and is considered a Class II drug (i.e.  low solubility and high 
permeability) by the Biopharmaceutics Classification System (BCS).8 Meloxicam has 
variable aqueous solubility related to its pH dependent ionization states. Under acidic 
conditions meloxicam is present in solution in its cationic form, while in basic solutions it 
is present in its anionic form. When the molecule is neutral in charge it will either be in 
its zwitterionic or enolic form depending on the polarity of the solvent.9-10 The different 
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ionization states of meloxicam are shown in Figure 3.1. Due in part to its low solubility 
under acidic conditions the Tmax (time to reach maximum concentration) of meloxicam in 
the human body is typically four to six hours, while it can take more than two hours for 
the drug to reach its therapeutic concentration in humans.11  
 
 
Figure 3.1 Meloxicam and its ionization states. 
 
 The slow onset of meloxicam prevents it from potential application for the relief 
of mild to medium level acute pain. To accelerate its onset of action, various complexes 
of meloxicam have been prepared and evaluated with respect to aqueous solubility, 
including cyclodextrin inclusion complexes,12 various solvates,7 ethanolamine,13  
ammonium and sulfate salts,9 or metal complexes with potassium and calcium.14 
Preparation of polymorphic crystal forms of meloxicam10 has also been attempted,  
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although unsuccessfully, to improve its dissolution profile.15-16  In spite of all the efforts 
that have been taken, a faster onset oral dosage form for meloxicam (i.e. 30 minutes or 
less) does not exist at this time. 
Unique crystalline forms tend to exhibit distinctive physicochemical properties 
effecting the dissolution, manufacturing, physical stability, permeability, and oral 
bioavailability of an API.17-19 A typical crystal form selection process comprises two 
stages of development after a target API has been selected: discovery of as many 
pharmaceutical crystal forms as possible and examination of the physicochemical 
properties of the newly discovered crystal forms. When salt formation, amorphous 
dispersions, particle size reductions, and formulation changes fail to improve solubility 
and subsequent bioavailability the more recent technology of pharmaceutical 
cocrystallization can be employed. A given API may form cocrystals with numerous 
pharmaceutically acceptable and/or approved materials, and these cocrystals could 
exhibit enhanced solubility20-23 and/or stability to hydration or compressibility.24 At the 
stage of crystal form discovery, two primary approaches are used.  The more 
straightforward approach is largely based on trial-and-error (e.g. high throughput crystal 
form screening) and has been implemented to discover crystal forms including, but not 
limited to, salts,18 hydrates,25 solvates,26 and, more recently, cocrystals.27,28-29 The 
alternative approach for crystal form discovery is the supramolecular synthon approach,30 
which recognizes supramolecular synthons31 as a design tool and can be more selective, 
time-efficient and cost-effective. The supramolecular synthon approach uses crystal 
engineering32-40 to carefully analyze the relevant supramolecular arrangements that an 
API might exhibit by utilizing the  Cambridge Structural Database (CSD),41 and 
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effectively prioritize all possible guest molecules for crystal form screening. Such an 
approach can be generally effective but has found particular success in generating 
pharmaceutical cocrystals.30, 42  
Pharmaceutical cocrystals represent an opportunity to diversify the number of 
crystal forms of a given API and in turn fine tune or even customize its physicochemical 
properties without the need for chemical (covalent) modification. There is no longer any 
doubt that cocrystals can change the physicochemical properties of a given API, however, 
the way these changes affect the pharmacokinetic (PK) profile is not predictable and is 
not yet fully understood due in part to the limited number of animal studies reported in 
the literature. 23, 43-51 These examples, discussed in Chapter 1, do however provide a solid 
foundation for pharmaceutical cocrystals as a tool to fine tune physicochemical and 
subsequent PK properties of API’s without making or breaking a covalent bond.  
While the work presented herein was being performed a report on cocrystals of 
meloxicam with carboxylic acids by grinding surfaced.52 
 Compared to other drugs in the same class, such as piroxicam, meloxicam is 
preferred due to its ability to selectively inhibit cyclooxygenase-2 (COX-2).53-54 The only 
difference between these two API’s is a pyridine ring on the amide linkage for piroxicam 
versus a thiazole ring on meloxicam. Between a previous report on piroxicam cocrystals 
with carboxylic acids55 and CSD analysis, pharmaceutical cocrystallization of meloxicam 
with carboxylic acids56 represents a promising approach to diversify the crystal form 
portfolio to be used to improve the relevant aqueous solubility and accelerate the onset of 
action for acute mild to medium level pain relief. Indeed a recent report on PK analysis in 
rats for an aspirin:meloxicam cocrystal resulted in a 44 fold increase in kinetic solubility 
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and a 4.4 fold increase in bioavailability.57 That study utilized previously reported 
toxicological information resulting from co-administration of meloxicam and aspirin. The 
rate limiting step in absorption and subsequent bioavailability of a BCS class II API is 
solubility since as it dissolves and readily absorbs due to its high permeability sink 
conditions are created. Synthesis and rat PK analysis for a set of meloxicam 
pharmaceutical cocrystals is presented with this in mind.  
 
3.2 Experimental Details 
3.2.1. Materials 
Meloxicam was purchased from Jai Radhe Sales, India with a purity of 99.64% 
and was used without further purification. All other chemicals were supplied by Sigma-
Aldrich and used without further purification. 
3.2.2 Methods 
 Meloxicam was reacted with 11 selected coformers: fumaric acid, succinic acid, 
maleic acid, malonic acid, gentisic acid, 4-hydroxybenzoic acid, adipic acid, (+)-
camphoric acid, glycolic acid, DL-malic acid, and α-ketoglutaric acid. All coformers 
produced at least one meloxicam cocrystal except α-ketoglutaric acid. The 
cocrystallization attempts resulted in 10 cocrystals (1 – 10), many of which were 
prepared via multiple synthetic techniques including solvent-drop grinding58-59 and 
slurrying.  Single crystals suitable for X-ray diffraction were successfully prepared for 
two of the new cocrystals (1 & 2).  
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Synthesis of meloxicam:fumaric acid (2:1) cocrystal (1) – (a) solvent-drop grinding – 
0.088 g (0.250 mmol) meloxicam was ball-milled with 0.015 g (0.129 mmol) of fumaric 
acid and 50 μL of THF for 30 minutes, generating 1 in ca. 100% yield; (b) slurry – 0.880 
g (2.50 mmol) meloxicam and 0.150 g (1.29 mmol) of fumaric acid were slurried in 3 mL 
of THF overnight sealed under ambient conditions at ca. 250 rpm. The resulting solid was 
filtered and washed with THF. 1 was isolated in ca. 81% yield; (c) solution crystallization 
– 0.100 g (0.284 mmol) meloxicam and 0.330 g (0.284 mmol) of fumaric acid was 
dissolved in 9 mL of a THF and left to slowly evaporate resulting in single crystals of 1 
(ca. 31% yield). 
Synthesis of meloxicam:succinic acid (2:1) cocrystal (2) – (a) solvent-drop grinding – 
0.088 g (0.250 mmol) meloxicam was ball-milled with 0.015 g (0.127 mmol) of succinic 
acid and 50 μL of THF for 30 minutes, generating 2 in ca. 100% yield; (b) slurry – 0.880 
g (2.50 mmol) meloxicam and 0.150 g (1.27 mmol) of succinic acid were slurried in 3 
mL of THF overnight sealed under ambient conditions at ca. 250 rpm. The resulting solid 
was filtered and washed with THF. 2 was isolated in ca. 78% yield; (c) solution 
crystallization – 0.100 g (0.284 mmol) meloxicam and 0.017 g (0.142 mmol) of succinic 
acid was dissolved in 10 mL of 1:1 THF and left to slowly evaporate. Single crystals of 6 
(ca. 55% yield) grew concomitantly with meloxicam form I and succinic acid.  
Synthesis of meloxicam:maleic acid (1:1) cocrystal (3) – (a) solvent-drop grinding – 
0.175 g (0.498 mmol) meloxicam was ball-milled with 0.058 g (0.498 mmol) of maleic 
acid and 40 μL of THF for 30 minutes, generating 3 in ca. 100% yield; (b) slurry – 0.750 
g (2.13 mmol) meloxicam and 0.248 g (2.13 mmol) of maleic acid were slurried in 2 mL 
of THF overnight sealed under ambient conditions at ca. 250 rpm. The resulting solid was 
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filtered and washed with the same solvent employed for the slurry. 3 was isolated in ca. 
92% yield.  3 can also be synthesized via ethyl acetate slurry. 
Synthesis of meloxicam:malonic acid (1:1) cocrystal (4) – (a) solvent-drop grinding – 
0.175 g (0.498 mmol) meloxicam was ball-milled with 0.052 g (0.498 mmol) of malonic 
acid and 40 μL of THF for 30 minutes, generating 4 in ca. 100% yield; (b) slurry – 0.900 
g (2.56 mmol) meloxicam and 0.266 g (2.56 mmol) of malonic acid were slurried in 2 
mL of THF overnight sealed under ambient conditions at ca. 250 rpm. The resulting solid 
was filtered and washed with THF. 4 was isolated in ca. 88% yield.  
Synthesis of meloxicam:gentisic acid (1:1) cocrystal (5) – (a) solvent-drop grinding – 
0.175 g (0.498 mmol) meloxicam was ball-milled with 0.077 g (0.498 mmol) of gentisic 
acid and 40 μL of chloroform or THF for 30 minutes, generating 5 in ca. 100% yield; (b) 
slurry – 0.850 g (2.41 mmol) meloxicam and 0.373 g (2.41 mmol) of gentisic acid were 
slurried in 2 mL of chloroform overnight sealed under ambient conditions at ca. 250 rpm.  
The resulting solid was filtered and washed with the same solvent employed for the 
slurry. 5 was isolated in ca. 85% yield. 5 can also be synthesized via slurry in ethyl 
acetate.  
Synthesis of meloxicam:4-hydroxybenzoic acid (1:1) cocrystal (6) – solvent-drop 
grinding – 0.175 g (0.498 mmol) meloxicam was ball-milled with 0.069 g (0.498 mmol) 
of 4-hydroxybenzoic acid and 40 μL of THF for 30 minutes, generating 6 in ca. 100% 
yield.  
Synthesis of meloxicam:adipic acid (2:1) cocrystal (7) – (a) solvent-drop grinding – 
0.088 g (0.250 mmol) meloxicam was ball-milled with 0.018 g (0.123 mmol) of adipic 
acid and 50 μL of THF for 30 minutes, generating 7 in ca. 100% yield; (b) slurry – 0.880 
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g (2.50 mmol) meloxicam and 0.180 g (1.23 mmol) of adipic acid were slurried in 3 mL 
of THF overnight sealed under ambient conditions at ca. 250 rpm. The resulting solid was 
filtered and washed with THF. 7 was isolated in ca. 80% yield.  
Synthesis of meloxicam:DL-malic acid (2:1) cocrystal (8) – (a) solvent-drop grinding – 
0.088 g (0.250 mmol) meloxicam was ball-milled with 0.017 g (0.127 mmol) of DL-
malic acid and 50 μL of THF for 30 minutes, generating 8 in ca. 100% yield; (b) slurry – 
0.880 g (2.50 mmol) meloxicam and 0.170 g (1.27 mmol) of DL-malic acid were slurried 
in 3 mL of THF overnight sealed under ambient conditions at ca. 250 rpm. The resulting 
solid was filtered and washed with THF. 8 was isolated in ca. 79% yield.  
Synthesis of meloxicam:(+)-camphoric acid (3:2) cocrystal (9) – (a) solvent-drop 
grinding – 0.233 g (0.663 mmol) meloxicam was ball-milled with 0.886 g (0.042 mmol) 
of DL-malic acid and 50 μL of chloroform for 30 minutes, generating 9 in ca. 100% 
yield; (b) slurry – 0.700 g (1.99 mmol) meloxicam and 0.266 g (1.33 mmol) of (+)-
camphoric acid were slurried in 4 mL of chloroform overnight sealed under ambient 
conditions at ca. 250 rpm. The resulting solid was filtered and washed with chloroform. 9 
was isolated in ca. 91% yield.  
Synthesis of meloxicam:glycolic acid (1:1) cocrystal (10) – (a) solvent-drop grinding – 
0.175 g (0.498 mmol) meloxicam was ball-milled with 0.038 g (0.498 mmol) of glycolic 
acid and 40 μL of chloroform for 30 minutes, generating 10 in ca. 100% yield; (b) slurry 
– 0.950 g (2.70 mmol) meloxicam and 0.206 g (2.70 mmol) of glycolic acid were slurried 
in 2 mL of ethyl acetate overnight sealed under ambient conditions at ca. 250 rpm.  
The resulting solid was filtered and washed with ethyl acetate. 10 was isolated in ca. 92% 
yield.  
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Crystal Form Characterization 
Quality single crystals for X-ray diffraction were obtained for two compounds, 1 
and 2. Attempts to crystallize 3-10 did not afford crystals suitable for single crystal X-ray 
crystallographic analysis. Single crystal analysis for 1-2 was performed on a Bruker-AXS 
SMART APEX CCD diffractometer with monochromatized Cu Kα radiation (λ = 
1.54178 Å). Data for 1 - 2 were collected at 100 K. Lattice parameters were determined 
from least-squares analysis, and reflection data were integrated using SAINT.60 
Structures were solved by direct methods and refined by full matrix least squares based 
on F2 using the SHELXTL package.61 All non-hydrogen atoms were refined with 
anisotropic displacement parameters. All hydrogen atoms bonded to carbon, nitrogen, 
and oxygen atoms were placed geometrically and refined with an isotropic displacement 
parameter fixed at 1.2 times Uq of the atoms to which they were attached. Hydrogen 
atoms bonded to methyl groups were placed geometrically and refined with an isotropic 
displacement parameter fixed at 1.5 times Uq of the carbon atoms. 
Powder X-Ray Diffraction (PXRD): 1-10 were characterized using a D-8 Bruker X-ray 
Powder Diffractometer using Cu Kα radiation (λ = 1.54178 Å), 40 kV, 40 mA. Data were 
collected over an angular range of 3 ° to 40 ° 2θ value in continuous scan mode using a 
step size of 0.05 ° 2θ value and a scan rate of 5 º/min.   
Calculated PXRD: Calculated PXRD diffractograms were generated from the single 
crystal structures of 1-2 using Mercury 2.2 (Cambridge Crystallographic Data Centre, 
UK) for the following complexes and compared to the pattern obtained for the 
corresponding bulk sample. 
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Differential Scanning Calorimetry (DSC): DSC was performed on a Perkin Elmer 
Diamond Differential Scanning Calorimeter with a typical scan range of 25 ºC – 280 ºC, 
scan rate of 10 ºC/min, and nitrogen purge of ca. 30 psi. 
Fourier Transform Infrared Spectroscopy (FT-IR):  FT-IR analysis was performed on 
a Perkin Elmer Spectrum 100 FT-IR spectrometer equipped with a solid-state ATR 
accessory. 
Pharmacokinetic Study 
Eight week old male Sprague-Dawley rats with a jugular vein catheter were 
purchased from Charles River Laboratories, Inc. and housed in a temperature-controlled 
room for at least 48 hours before the PK study. All animal experiments in the present 
study were approved by the Institutional Animal Care and Use Committee (IACUC). The 
rats, n = 5, were fasted over night and weighed immediately before dosing. Ten mg/kg of 
meloxicam or its equivalent (for cocrystals) were prepared, sieved to a particle size range 
between 53 and 75 μm, and suspended in 1 ml of 5% polyethylene glycol 400 (PEG 400) 
with 95% methylcellulose solution (weight percentage) and administered in a single dose 
suspension via oral gavage in a single dose.  Serial blood samples (0.2 mL) were obtained 
from the catheter at 0, 0.25, 0.5, 0.75, 1, 2, and 4 hours after oral administration. Blood 
samples were centrifuged with an Eppendorf Centrifuge at 3000 rpm, 4 ºC, for 10 min in 
order to obtain serum samples. All serum samples were stored at -80 ºC for subsequent 
HPLC analysis. 
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HPLC Analysis. 
 A 12.5 µg/mL piroxicam methanol solution was used as the internal standard (IS). 
50 µL of animal plasma sample was transferred into an individual Eppendorf 
microcentrifuge tube and 200 µL IS working solution was added. Each Eppendorf 
microcentrifuge tube was hand shaken well and the sample was allowed to sit for 20 min. 
Each Eppendorf microcentrifuge tube was shaken again and the sample was transfered 
into a 0.2 µm Nylon-66 Microfilterfuge tube (Rainin, Oaklong, CA), and spun at 10,000 
rpm for 4 min. Clear methanol solutions (200 µL or less) with meloxicam were separated 
from serum proteins and 160 µL of clear methanol solution was transferred into 
individual HPLC vials. HPLC analysis was carried out on a Perkin Elmer Instruments 
LLC comprising the following units: Series 200 Gradient Pump; 785A UV/VIS Detector; 
Series 200 Autosampler; NCI 900 Network Chromatography Interface and 600 Series 
Link. The machine was operated by Total Chrome Workstation (Perkin Elmer 
Instruments LLC). Sample holder temperature was at 4o C and a 250 x 4.6 mm x 1/4” 
Microsorb-MV 300-5 C-18 column was used. The analytes were eluted with a mixture of 
phosphate buffer (pH 3.0) and methanol (1/1, v/v).  The temperature of the column was 
set at 40 °C with a flow rate of 1 mL/min, an injection volume of 20 μL, and absorbance 
was measured at 360 nm.  
PK Parameters and Statistical Analysis 
Microsoft Excel 2007 was used to process the PK data and generate statistics, one 
way analysis of variance (ANOVA) was used. 
 
 
 77
3.3 Results and Discussion 
3.3.1 Cambridge Structural Database Analysis 
As previously mentioned, a key step in generating pharmaceutical cocrystals is to 
analyze the target API from a crystal engineering perspective, i.e. to evaluate how the 
target molecule would form supramolecular synthons. This methodology partitions the 
target molecule by its functional groups and statistically62 examines the percentage of 
occurrence of supramolecular homo- and heterosynthons for these functional groups. The 
targeted supramolecular synthons are typically sustained via hydrogen bonds as they are 
strong and directional in nature.  This method is particularly beneficial as most API’s 
tend to be rich in functional groups that are capable of forming strong hydrogen bonds.   
Polymorphic form I63 of meloxicam indicates that meloxicam molecules form 
supramolecular chains that are sustained by sulfonyl-amide and thiazole-alcohol 
supramolecular heterosynthons, as shown in Figure 3.2. The chains are held together by 
various weak interactions, stacking along the a-axis in a slipped fashion. Thus for 
meloxicam cocrystallization, one or all of these supramolecular synthon motifs must be 
interrupted.55  
 
Figure 3.2: Meloxicam supramolecular chains sustained by sulfonyl:amide dimers 
and thiazole-alcohol supramolecular synthons, CSD Refcode SEDZOQ. 
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A CSD analysis64 was conducted to examine the occurrence of supramolecular 
synthon formation. First a search for an amide-thiazole (5-membered ring, containing a 
nitrogen and a sulfur atom, linked to a primary amide) was conducted resulting in zero 
entries therefore the structure was narrowed down to an amino-thiazole functionality (5-
membered ring, containing a nitrogen and a sulfur atom, linked to a primary amine) 
resulting in five entries. When this structure was searched in the presence of a carboxylic 
acid, primary amide, or alcohol moiety the result was zero entries. The search was then 
narrowed further employing a simple thiazole (5-membered ring containing one nitrogen 
atom and one sulfur atom). The reliability of supramolecular heterosynthon versus 
homosynthon formation between a thiazole and a carboxylic acid, primary amide, and 
alcohol were then examined in the CSD.  
Due to the inability of the thiazole to form a supramolecular synthon with itself; 
only the homosynthon formation of the carboxylic acid, primary amide, and alcohol 
moieties in the presence of a thiazole was examined. Any conclusions from the limited 
data set might not be statistically significant due to the low number of hits for each 
search, however, heterosynthon formation was favored for carboxylic acids and alcohols, 
Table 3.1. 
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Table 3.1: CSD statistics for thiazole supramolecular synthons.64 
Search Type 
 
Total # of 
Entries 
Homosynthon
(%) of total 
Heterosynthon
(%) of total 
Thiazole (N as acceptor) - Acid 22 31.8 40.9 
Thiazole (S as acceptor) - Acid 22 31.8 4.5 
Thiazole (N as acceptor) - Amide 15 60 13.3 
Thiazole (S as acceptor) - Amide 15 60 0 
Thiazole (N as acceptor) - Alcohol 80 7.5 10 
Thiazole (S as acceptor) - Alcohol 80 7.5 13.8 
 
Based on the preference of supramolecular heterosynthon formation between 
thiazoles and carboxylic acids, a meloxicam cocrystal screen with acidic coformers that 
are generally recognized as safe (GRAS) or pharmaceutically acceptable and/or approved 
was conducted. The focus of the study was rather narrow in scope and did not include 
coformers that only possessed alcohol moieties despite the potential for interaction based 
upon the CSD statistics. Meloxicam was thereby reacted with fumaric acid, succinic  
acid, maleic acid, malonic acid, gentisic acid, 4-hydroxybenzoic acid, adipic acid, (+)-
camphoric acid, glycolic acid, DL-malic acid, and α-ketoglutaric acid. All coformers 
except α-ketoglutaric acid produced at least one cocrystal.  
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The cocrystallization attempts resulted in 10 crystal forms; namely, 
meloxicam:fumaric acid cocrystal, meloxicam:succinic acid cocrystal, meloxicam:maleic 
acid cocrystal, meloxicam:malonic acid cocrystal, meloxicam:gentisic acid cocrystal, 
meloxicam:4-hydroxybenzoic acid cocrystal, meloxicam:adipic acid cocrystal, 
meloxicam:(+)-camphoric acid cocrystal, meloxicam:glycolic acid cocrystal, and 
meloxicam:DL-malic acid cocrystal. Table 3.2 contains chemical diagrams of the 
cocrystal formers, melting points, and pKa information.  
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Table 3.2: Molecular diagrams, pKa information, and melting points for meloxicam 
and cocrystals 1 - 10. 
 
Name Molecular structure  
 
pKa ΔpKa Ratio  
Meloxicam : 
Coformer 
MP of 
coformer 
(oC) 
MP of 
cocrystal 
(oC) 
Meloxicam 
 See Figure 3.1 
4.18 N/A N/A 254 N/A 
Fumaric Acid   (1) HO
O
O
OH
3.1 1.08 2:1 287 240 
Succinic Acid  (2) HO
O
O
OH
4.19 -0.01 2:1 185 226 
Maleic Acid (3) 
OH
O
O
OH
 
1.93 
 
 
 
2.25 1:1 137 
 
 
 
192 
 
 
 
Malonic Acid (4) 
HO
O O
OH
2.83 
 
1.35 1:1 134 
 
164 
 
Gentisic Acid (5) 
HO OH
O
OH 2.98 
 
 
 
1.20 1:1 203 
 
 
 
237 
 
 
 
4-Hydroxybenzoic 
Acid (6) O
HO
OH
 
4.58 
 
 
 
 
-0.40 1:1 214 
 
 
 
 
209 
 
 
 
 
Adipic Acid (7) 
O
HO
O
OH
 
4.42 
 
 
-0.24 2:1 152 
 
 
209 
 
 
DL-Malic Acid        
(8) HO
O OH
OH
O  
3.40 
 
 
 
 
0.78 2:1 131 
 
 
 
 
215 
 
 
 
 
(+)-Camphoric 
Acid (9) 
HO
O
O
OH  
4.70 -0.52 3:2 183 
 
 
 
212 
 
 
 
Glycolic Acid (10) 
OH
O
HO
 
3.83 
 
 
 
0.35 1:1 75 
 
 
 
163 
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3.3.2 Crystal Structure Descriptions 
Meloxicam:Fumaric Acid (2:1) Cocrystal, 1 
The asymmetric unit of the meloxicam:fumaric acid cocrystal (1) contains two 
meloxicam molecules and one fumaric acid molecule which crystallizes in the space 
group Pī. In 1, the meloxicam dimer persists and links to adjacent dimers via fumaric 
acid molecules, creating an infinite supramolecular chain, Figure 3.3. The supramolecular 
heterosynthon comprising carboxylic acid and thiazole/NH moieties is a two point 
recognition observed between fumaric acid and meloxicam.  Both O-H???N and NH???O 
hydrogen bonds are observed [O22-H22O???N3: O???N 2.68(3) Å, H???N 1.821 Å, O-
H???N 174.39 º; N2-H2???O21: N???O 2.857(4) Å, H???O 1.976 Å, N-H???O  160.49 º]. The 
supramolecular chains of meloxicam and fumaric acid exhibited in 1 present as stacked 
layers, Figure 3.4. 
 
 
 
Figure 3.3: Supramolecular synthons observed in Meloxicam:Fumaric Acid (2:1), 
Cocrystal 1. 
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 Figure 3.4: Supramolecular layers stacking in Meloxicam:Fumaric Acid (2:1), 
Cocrystal 1. 
 
 
Meloxicam:Succinic Acid (2:1) Cocrystal, 2 
 Preparation of the meloxicam:succinic acid cocrystal (2) by solvent-drop grinding 
has been recently reported but without determination of its crystal structure.52  The 
calculated PXRD of 2 based upon this single crystal structure data matches that of the 
previously reported PXRD. 2 crystallizes in the space group Pī with the asymmetric unit 
containing one meloxicam molecule and half a succinic acid molecule. The crystal 
structure of 2 reveals that the meloxicam dimers are associated with adjacent dimers by 
succinic acid molecules forming infinite supramolecular chains, Figure 3.5. Similar to 
previous meloxicam cocrystal structures, the primary intermolecular interactions of 2 are 
hydrogen bonds between meloxicam and succinic acid via the carboxylic acid to 
thiazole/NH supramolecular heterosynthon. The OH???N and NH???O=C hydrogen bonds 
are involved [O7-H7???N3: O???N 2.863(4) Å, H???N 1.847 Å, O-H???N 173.63 º; N2-
H2???O6: N???O 2.849(4) Å, H???O 1.993 Å, N-H???O 164.32º]. The supramolecular 
chains of meloxicam and succinic acid in 2 are reminiscent of the supramolecular chains 
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found in 1, Figure 3.5. As shown in Figure 4.6, supramolecular chains of succinic acid 
and meloxicam stack with an interplanar spacing of 3.386 Å. As a result of overall 
packing comparison between meloxicam cocrystal structures, it is observed that the 
crystal structures of 1 and 2 are isostructural. Table 3.3 lists the crystallographic details 
for 1 and 2. 
 
Figure 3.5: Supramolecular synthons observed in Meloxicam:Succinic Acid (2:1), 
Cocrystal 2. 
 
 
Figure 3.6: Supramolecular layers stacking in Meloxicam:Succinic Acid (2:1), 
Cocrystal 2. 
 
 
 85
  
Table 3.3: Crystal structure parameters for 1 and 2. 
 1 2 
Chemical formula (C14H13N3O4S2)2.
 C4H4O4 
(C14H13N3O4S2)2. 
C4H6O4  
 
Formula weight 818.86 820.88 
Crystal 
System 
Triclinic Triclinic 
Space group Pī Pī 
a (Å) 7.145(5) 7.2315(4) 
b (Å) 8.475(5) 8.4994(5) 
c (Å) 15.088(9) 14.9383(8) 
α (o) 82.250(9) 82.741(4) 
β (o) 81.368(9) 80.061(3) 
γ (o) 70.519(9) 70.313(4) 
Vol (Å3) 848.1(7) 849.21(8) 
Dcal (g cm-3) 1.603 1.605 
Z 1 1 
Reflections collected 4399 5052 
Independent reflections  3031 2719 
Observed reflections    2298 1871 
T (K) 100 100 
R1 0.0451 0.0463 
wR2 0.1067 0.0845 
GOF 0.995 0.995 
 
3.3.3 Meloxicam Crystal Forms: Cocrystals or Salts? 
Pharmaceutical cocrystals and salts are well defined and are typically classified as 
distinct subsets of crystal forms. Whether the meloxicam crystal forms generated by the 
10 coformers in this study are cocrystals or salts has also been addressed. For crystal 
forms with single crystal XRD data (i.e. 1-2), the conclusion that 1-2 are cocrystals was 
drawn in a relatively simple and reliable manner. However, it was less straightforward to 
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identify whether 3-10 are cocrystals or salts. The pKa values for meloxicam are 1.09 and 
4.18.65  The value of 1.09 is associated with the enolic OH group while the value of 4.18 
is linked to the nitrogen atom on the sulfathiazole ring. The enolic OH is much less 
accessible from a crystal engineering perspective as it is involved in intramolecular 
hydrogen bonding to the neighboring ketone or NH moieties. In contrast, the nitrogen 
atom on the thiazole ring is the primary target for cocrystal or salt formation, as it could 
potentially sustain a supramolecular synthon with various hydrogen bond donors.  
ΔpKa is widely accepted as a guidline to predicting whether a salt or cocrystal will 
form.66-69 It is generally considered that, if ΔpKa < 0, the resulting compound will be a 
cocrystal, whereas the result is typically a salt if ΔpKa >3.  For the region of ΔpKa 
between 0 < ΔpKa < 3,  our ability to predict whether the resulting complex will be 
neutral or charged is limited.68 Indeed, ca. half of the ΔpKa values reported herein fall 
into the range of 0 < ΔpKa < 3 so how can one identify whether 3-10 are cocrystals or 
salts, especially where the FT-IR spectra may not provide adequate information? 
The ΔpKa value of cocrystal 1, which has structural data, was used as a reference 
to determine whether 3-10 are cocrystals or salts. As shown in Table 3.2, 1 possesses a 
ΔpKa of 1.08 and proton transfer was not observed between meloxicam and fumaric acid.  
Although the molecular arrangement of various coformers may have an influence to the 
electron distribution and protonation of meloxicam, with the single crystal XRD data of 
2, it is reasonable to assert that all but one of the coformers involved in this study with 
ΔpKa values close to or less than 1.08 would potentially produce a cocrystal rather than a 
salt with meloxicam.70 Based on this, with the exception of 3, all crystal forms prepared 
in this study can be identified as meloxicam cocrystals. Since 3 remained questionable 
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due to a ΔpKa of 2.25 further investigation into the FT-IR spectrum was performed to 
help identify the position of the proton. The carbonyl group of maleic acid in 3 exhibits a 
distinct peak at 1716 cm-1, indicating that the carboxylic acid group is neutral rather than 
negatively charged.71 Therefore, proton transfer does not occur between meloxicam and 
maleic acid and it is deemed a cocrystal in agreement with Myz et al.52 
    
3.3.4 Cocrystal Stoichiometries  
Cocrystals 3 - 5 and 7 - 10 were prepared from both solution and solid-state 
grinding methods, while 6 was only produced by solvent drop grinding.  The absence of 
structural data for 3 - 10 is the result of unsuccessful solution-based growth attempts for 
single crystals. Nevertheless, polycrystalline powders of 3-10 were characterized by 
PXRD, FT-IR, and DSC, see Appendix 2. As mentioned in section 3.1 Myz et al. 
reported cocrystals of meloxicam by grinding with succinic acid (1:1) and maleic acid 
(1:2) but the stoichiometric ratio presented here for the succinic acid cocrystal, 2 here, 
was 2:1 and for maleic cocrystal, 3 here, 1:1. Furthermore, no single crystal data was 
produced by Myz, but only FT-IR and PXRD data. Even without the single crystal XRD 
data, the stoichiometries of 3-10 were determined by DSC or NMR in compliment with 
FT-IR and PXRD data as exemplified by 3. Based on the potential supramolecular 
interactions of meloxicam and the lack of ratio in the previous report, the most likely 
stoichiometry of meloxicam and maleic acid in 3 was proposed to be either 1:1, 2:1, or 
1:2 (API:former). In order to determine the stoichiometry of 3, ethyl acetate slurries of 
physical mixtures of meloxicam and maleic acid in molar ratios of 2:1, 1:1, and 1:2 were 
performed at room temperature overnight. From each slurry experiment, the solid 
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crystalline powder was separated, washed with ethyl acetate and dried for 
characterization. The absence of pure maleic acid, water, or ethyl acetate was confirmed 
based on the DSC analysis, Figure 3.8, upon all three solid powders from the slurries. 
PXRD characterization indicated that the solids generated from the 1:1 and 1:2 slurries 
were identical to the cocrystal form from the initial solvent drop grind experiment 
conducted at a 1:1 ratio. In contrast, the 2:1 slurry produced a physical mixture of 
meloxicam form I and the cocrystal as confirmed by PXRD, Figure 3.7. 1H NMR 
(nuclear magnetic resonance) analysis (400 MHz, d6-DMSO) on solids from the 1:1, 2:1, 
and 1:2 slurries confirmed that the stoichiometry of meloxicam and maleic acid in 3 is 
1:1. PXRD, NMR, FT-IR, and DSC data can be found in Appendix 2.  
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Figure 3.7: PXRD patterns for Meloxicam:Maleic Acid slurries. 
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 Figure 3.8: DSC of Meloxicam:Maleic Acid slurries.
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3.3.5 In vivo Performance via Rat Pharmacokinetic Studies  
 The PK profiles of 10 meloxicam:carboxylic acid cocrystals and pure meloxicam 
were determined and evaluated with respect to serum concentration in male Sprague-
Dawley rats over four hours via a single oral dose of 10 mg/kg equivalent of meloxicam, 
Figure 3.9. The time versus concentration profile for many of the crystal forms continued 
to increase throughout most of the study.  Cocrystals 7 and 8 had serum concentrations 
that were still increasing at four hours. An intravenous (IV) leg was not conducted 
therefore bioavailability was not obtainable, however, Cmax, Tmax, and AUC over four 
hours are shown in Table 3.4. Cocrystals 2, 4, and 9 decreased Tmax significantly over the 
time of the study, although, since pure API and two of the cocrystals are still increasing at 
four hours this information could be misleading with respect to long term action.  
 In terms of onset of action the fifteen minute data point is intriguing as it reveals 
that seven of the cocrystals reach higher serum concentrations; 6 is 2.73 fold higher, 3 is 
2.42 fold higher, while 5 and 9 are ca. 2 fold higher. This could result in faster 
therapeutic levels in clinical studies and warrants further investigation. The Cmax values 
over four hours increased for five of the cocrystals compared to meloxicam with 7 and 8 
reaching ca. 25% higher values. AUC values increased for five of the ten cocrystals (2, 3, 
6, 7, and 8) with the largest differences attributed to 2 and 6.  
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 Figure 3.9: Serum concentration for meloxicam and meloxicam cocrystals in rats over 4 hours. 
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Table 3.4: Pharmacokinetic data for meloxicam and meloxicam cocrystals. 
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 The therapeutic concentration of meloxicam is achieved after ca. 2 hours in 
humans for the currently marketed oral dosage form11  and for comparison purposes the 
concentration of pure meloxicam as determined herein at 2 hours, 30.19 μg/mL, will be 
used as a reference for further discussion although it should be noted that efficacy was 
not assessed here. Cocrystals 1, 4, 5, 9, and 10 had serum concentrations equal to or less 
than pure meloxicam at 2 hours, while 2, 3, and 6 - 8 were greater. Figure 3.9 indicates 
five cocrystals have outperformed pure API at the two hour point. 2 achieved the highest 
serum concentration at 2 hours (44.02 μg/mL), while 10 had the lowest concentration 
(20.77 μg/mL). The meloxicam:fumaric acid cocrystal, 1, has an interesting PK profile in 
that it is relatively linear over 4 hours making it suitable for possible application as a 
controlled release form.  
 Melting point is sometimes related to solubility due to the strength of the 
interactions involved in the crystalline lattice. The lower the melting point of a substance 
the easier it may be to dissolve that substance in GI fluids therefore correlations between 
cocrystal melting points and serum concentrations, AUC’s, and coformer melting points 
were investigated. It was found that only the correlation between cocrystal and coformer 
melting points exhibited a weak linear trend with an R2 value of 0.636. Predicted aqueous 
solubilities72 were also used to investigate correlations with the PK data and no 
correlations were found. The lack of correlations with the PK data suggests that other 
physiological processes besides dissolution may be exerting their effects.  
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3.4 Conclusions 
 Nine meloxicam:carboxylic acid cocrystals have been discovered and the 
previously reported maleic acid cocrystal ratio was determined. Most of them can be 
synthesized by solvent drop grinding and slurry methods. Two of them, 1 and 2, 
produced single crystals suitable for X-ray diffraction resulting in reliable structural data. 
These two cocrystals are isostructural which is not surprising considering the only 
difference between these two coformers is a double bond. Interestingly two of the diacids 
here produced 1:1 stoichiometries while five others produced 2:1 stoichiometries. In the 
case of 3 this could be explained by intramolecular hydrogen bonding due to the cis 
conformation of maleic acid resulting in the H-bonding functionalities being less 
available to partake in supramolecular synthons.  
 Five of the cocrystals performed worse than pure meloxicam in PK analysis in 
rats and five others performed better with respect to Cmax and AUC. Cocrystal 8 achieved 
a 26.2% increase in Cmax compared to pure meloxicam and 2 achieved a 36.4% increase 
in AUC compared to pure meloxicam. At fifteen minutes seven of the cocrystals reached 
a higher serum concentration with 6 exhibiting a 2.73 fold increase, which could lead to 
faster onset in terms of therapeutic levels in clinical studies and warrants further 
investigation of this and the other crystal forms that out performed meloxicam at this time 
point. 
 As an oral dosage form reaches the gastrointestinal (GI) tract, it must first be 
dissolved in GI fluids before it can be absorbed. During this process many different 
physiological molecules such as enzymes, hormones, second messengers, and 
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immunological compounds may be present and actively interfering. Undoubtedly these 
physiological factors will also affect the absorption of the API. Since meloxicam is 
highly permeable (BCS class II) solubility is the limiting factor for absorption. However, 
permeability may also be affected by the use of cocrystals. In this case that effect may be 
insignificant or overlooked due to its inherently high permeability. It is well accepted that 
cocrystals represent a way to affect the solubility of an API, but how this affects the in 
vivo performance of that API remains to be fully understood or predictable.  
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Chapter 4: Crystalline Forms of (R,S) Baclofen: A Zwitterionic Active 
 
Pharmaceutical Ingredient 
 
4.1 Background 
 
Oral dosage forms approved by regulatory agencies, such as the Food and Drug 
Administration (FDA), are typically stable crystalline forms whether they be in tablet, 
capsule, or suspension form. Different crystalline forms include, but are not limited to, 
salts1, hydrates2, solvates3, and, more recently, cocrystals4-5. Novel crystalline forms can 
tune solubility by changing the thermodynamic properties of the solid which is of seminal 
importance when considering oral dosage forms.6 Polymorphs, different packing 
arrangements of the same molecule, can also exhibit different solubilities although those 
differences are usually small due to the nature of small differences in crystal packing.7 
However, in some rare cases of conformational polymorphism the difference in solubility 
can be very substantial as in the case of ritonavir since the crystal packing is significantly 
different.8  Improving aqueous solubility through salt formation has been the gold 
standard approach for the pharmaceutical industry when low solubility, ionizable, APIs 
are involved.9 Crystal packing of a salt is usually very different than that of the conjugate 
acid or base which leads to different physicochemical properties such as rate of 
dissolution.10 Ionized molecules are generally far more water soluble than their neutral 
counterparts because they have a large increase in dipole moment which provides the 
basis for this approach.11 Not including APIs which are peptide hormones, antibodies, 
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proteins, polymeric, inorganic, or greater than 1000 Da in molecular weight, there were 
1356 compounds listed in the FDA’s Orange Book of approved drug products at the end 
of 2006.12 Of that total, 51.4% are salts with the majority of these salts formed from basic 
APIs where the most prevalent counterion is chloride (53.4% of these compounds). The 
most prevalent cation for acidic APIs was sodium (75.3% of these compounds). Logic 
dictates these as the most obvious choices since they are already prevalent in the human 
body. Different counterions will dictate different crystalline forms which will present a 
range of physicochemical properties9-10 as in the case of diclofenac where the sodium salt 
is used for delayed release tablets and the potassium salt for immediate release tablets 
since the two have significantly different dissolution rates.13  
The focus of this study is a low solubility zwitterionic API known as (R,S) 
baclofen or (R,S) β-amino-γ-(p-chlorophenyl)-butyric acid. Baclofen is an anti-spastic 
agent developed in the early 20th century for epilepsy that mimics γ-aminobutyric acid 
(GABA) and acts as an agonist for GABA b receptors which results in the reduction of 
excitatory neurotransmitter effects.14-15 It is a lipophilic derivative of GABA that can 
permeate the blood brain barrier which is delivered as the racemate. However, the R 
enantiomer is more active since it can attain the same conformation as GABA.16 It was 
quickly determined that it had minimal effects on epilepsy but was recognized for its 
ability to reduce spasticity in certain patients. Baclofen is most widely used by patients 
with spasticity related problems like cerebral palsy17-19, dystonia20, and trigeminal 
neuralgia21 but is also currently being investigated for numerous other indications like 
spinal cord injuries22-23, binge eating24, alcohol dependence25, and opiate addiction.26  
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There are oral and injectable dosage forms available at a maximum dose of 80 mg per 
day. Novartis marketed baclofen as Lioresal® and Medtronic has devised an intrathecal 
infusion pump for patients with severe spasticity.27  
Zwitterions are neutral amphoteric molecules that carry both a formal positive and 
negative charge. In an aqueous solution the ionization state is determined by the pH 
value. Amphoteric molecules in water have an isoelectric point (pI), which is the pH at 
which the zwitterionic conformation is stablized. Under normal circumstances if the pH 
is lowered below the pI then the molecule is protonated with a net positive charge and the 
opposite is true if the pH rises above the pI. With these pH changes the molecule 
becomes polarized and more soluble in water. Baclofen has a unique conformationally 
stabilized zwitterionic structure through intramolecular charge assisted H-bonding, 
Figure 4.1, that survives at a pH range of 5 - 8.5 creating a low solubility throughout this 
pH range.27  
 
 
 
Figure 4.1: Baclofens zwitterionic structure. 
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Currently baclofen precipitates out at concentrations above 2 mg/mL in water or 
at pH conditions near the pI, 6.7, which can cause the intrathecal pump mentioned earlier 
to clog or create inaccurate dosing.27  By manipulating the crystalline form of baclofen it 
is possible to increase the concentration in the infusion pump to allow for less physician 
visits involving surgical refills and reduce the risk of precipitation and subsequent 
overdose if the pump clogs up and bursts. 
The degree of proton transfer is the distinguishing factor between cocrystals and 
salts and is affected by the ionization constants28, however, in the case of gabapentin, a 
zwitterionic API similar to baclofen, a multiple component crystalline form exists with 4-
hydroxybenzoic acid where there appears to be partial proton transfer due to a disordered 
proton on a special position crystallographically with 50% occupancy.29 This is a rare 
case which could potentially complicate intellectual property (IP) arguments and 
patentability, however such rare cases cannot be ignored due to mounting evidence of the 
stability of such structures including but not limited to the conclusion of Mohamed et al. 
2009 where computational modeling revealed that a significant energy penalty is reduced 
when the presence of a disordered acidic proton is indicated.30 The study herein compares 
different multiple component crystal forms of (R,S) baclofen as sulfonate salts, on the 
basis of aqueous solubility under different pH conditions. The sulfonic acids used are 
depicted in Figure 4.2, which were chosen in order to break the interaction represented in 
Figure 4.1 with the thought that a strong enough acid would protonate the carboxylate. 
Structural comparisons, dissolution profiles in pure water, pH 1, and pH 7, and 
solubilities are discussed. 
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Figure 4.2: Sulfonic acids paired with baclofen. 
 
 
4.2 Experimental Details 
4.2.1 Materials 
 (R,S) Baclofen anhydrous was purchased from Spectrum and was used without 
further purification.  All other chemicals were supplied by Sigma-Aldrich and used 
without further purification. 
4.2.2 Methods 
Synthesis of (R,S) Baclofen monohydrate (1): (R,S) Baclofen was dissolved in 10% 
methanol, 0.68% acetic acid water with heat and left to evaporate. After one week 
colorless plates and needles were obtained with ca. 95% yield. 
Synthesis of (R,S) Baclofen:p-Phenolsulfonate (2): (R,S) Baclofen was dissolved in a 
65% by weight aqueous p-phenolsulfonic acid solution with heat to nearly saturated and 
then allowed to cool to room temperature. Colorless needles were obtained after cooling 
down in ca. 91% yield. 
 
107 
 
Synthesis of (R,S) Baclofen:4-Chlorobenzenesulfonate (3): (R,S) Baclofen and 4-
chlorobenzenesulfonic acid were dissolved in water with heat at a 1:1 stoichiometric ratio 
and the resultant solution was left to evaporate affording colorless plates and needles 
after 5 days in ca. 95% yield. Synthesis of 4 and 5 are discussed in section 4.5.2. 
Crystal Form Characterization   
Single-Crystal X-ray Diffraction: Single crystals were obtained for 3 
compounds.  Single crystal analysis for 1-5 was performed on a Bruker-AXS SMART 
APEX CCD diffractometer with Mo Kα radiation (λ = 0.71073 Å) connected to a 
KRYO-FLEX low-temperature device and collected at 100 K for 1-4 and 223 K for 5.  
Lattice parameters were determined from least-squares analysis and reflection data were 
integrated using SAINT.31  Structures were solved by direct methods and refined by full 
matrix least squares based on F2 using the SHELXTL package.32  All non-hydrogen 
atoms were refined with anisotropic displacement parameters. All hydrogen atoms 
bonded to carbon, nitrogen, and oxygen atoms were placed geometrically and refined 
with an isotropic displacement parameter fixed at 1.2 times Uq of the atoms to which they 
were attached.  Hydrogen atoms bonded to methyl groups were placed geometrically and 
refined with an isotropic displacement parameter fixed at 1.5 times Uq of the carbon 
atoms. 
Powder X-Ray Diffraction (PXRD): Powders were characterized by a D-8 
Bruker X-ray Powder Diffractometer using a Cu Kα radiation (λ = 1.54178 Å), 40kV, 
40mA. Data was collected over an angular range of 3° to 40° 2θ value in continuous scan 
mode using a step size of 0.05° 2θ value and a scan speed of 5.0 º/min.   
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Calculated PXRD: Calculated PXRD diffractograms were generated from the 
single crystal structures using Mercury 1.5 (Cambridge Crystallographic Data Centre, 
UK) for 1-5 for comparison to the bulk sample. 
Differential Scanning Calorimetry (DSC): Thermal analysis was performed on 
a TA Instruments DSC 2920 Differential Scanning Calorimeter. Aluminum pans were 
used for all samples and the instrument was calibrated using an indium standard.  
For reference, an empty pan sealed in the same way as the sample was used.  
Using inert nitrogen conditions, the samples were heated in the DSC cell from 30°C to 
the required temperature (melting point of the cocrystal) at a rate of 5°C/min unless 
otherwise specified. 
Fourier Transform Infrared Spectroscopy (FT-IR):  FT-IR analysis was 
performed on a Perkin Elmer Spectrum 100 FT-IR spectrometer equipped with a solid-
state ATR accessory. 
Thermogravimetric analysis (TGA): A Perkin Elmer STA 6000 Simultaneous 
Thermal Analyzer was used to conduct thermogravimetric analysis. Open alumina 
crucibles were used to heat the samples from 30°C to the required temperature at 10 
°C/min scanning rate under nitrogen stream. 
Dissolution and Solubility 
 Particle Size: Crystals were ground up and sieved to maintain a particle size 
range between 53 and 75 μm. 
  
109 
 
 High Performance Liquid Chromatography (HPLC): Analysis was performed 
on a Shimadzu Prominence HPLC system comprising the following units: an SIL 20AHT 
autosampler; a SPD 20A UV/vis Detector; a CBM 20A Communications Bus Module; 
LC20 AT Liquid Chromatograph; DGU 20A5 Degasser. The system was at room 
temperature and a flow rate of 1 mL/min was used. The column was a Thermo Scientific 
Hypersil ODS C-18 (100 _ 4.6 mm _ 5μm). The mobile phase consisted of a mixture of 
0.01 M phosphate buffer (pH 3.5) with acetonitrile (4/1, v/v).  
 Dissolution Study: Dissolution studies were performed on pure (R,S) baclofen, 2 
and 3 allowing for the salt forms to be compared against the original API. Deionized 
water, pH 1 aqueous solution (0.1 N HCl, 37o C), and a 0.8 M sodium phosphate buffer 
pH 7 were used all at 37o C. The dissolution study was conducted using an excess of free-
flowing solid in solution in 25 mL of solvent; for (R,S) baclofen 175 mg/beaker was used 
in water, 875 mg/beaker was used in 0.1 M HCl, and 150 mg/beaker was used in pH 7 
buffer; for 2, 3 g of solid was used in water, 3.5 g of solid was used in 0.1 M HCl, and 
250 mg/beaker was used in pH 7 buffer; for 3, 188 mg of solid was used in water and 425 
mg of solid was used 0.1 M HCl; The slurries were stirred with a magnetic stir bar at a 
rate of ca. 200-300 rpm. Aliquots were filtered with 0.45 μm filters after 1, 5, 10, 15, 30, 
60, 120, 240, 480, 720, and 1440 min (2880 min also for pH 7). The resulting solution 
was processed and the concentration of baclofen was measured using HPLC. The pH 
values of the resulting solutions and crystal forms of the solid in those solutions were also 
determined. The experiment was done in triplicate to allow for statistical analysis.33   
 pH Determination: pH was determined using a VWR SympHony pH meter 
model SP70P with a digital readout.   
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Photographs 
(R,S) Baclofen monohydrate (1): 1 was viewed with a fully automated, upright 
Zeiss Axio- Imager Z.1 microscope with a 20x /0.70NA dry objective.  
 
(R,S) Baclofen:p-Phenolsulfonate (2): 2 was viewed with a fully automated, 
upright Zeiss Axio- Imager Z.1 microscope with a 20x /0.70NA dry objective, and 
Nomarski DIC contrasting prisms.  Z-stacks of images were created at 0.5 micron step 
sizes using the AxioCam MRm CCD camera and Axiovision version 4.6.02 software 
suite.  Images were then 3-dimensionally reconstructed using the iso-surface technique in 
Bitplane’s (Zurich, Switzerland) Imaris software version 5.0.3. 
 
(R,S) Baclofen:4-Chlorobenzenesulfonate (3): 3 was viewed with an Olympus 
MIC-D digital microscope. 
 
4.3 Results and Discussion 
4.3.1 Pure Baclofen  
 The hydrochloride salt of (R) baclofen which crystallizes in the P212121 space 
group was deposited into the Cambridge Structural Database (CSD) in 1982.16 Each 
baclofen molecule is protonated by HCl to have a neutral carboxylic acid group and an 
ammonium group which counterbalances the chloride anion. The ammonium group is 
involved in charge assisted hydrogen bonding with three adjacent chloride anions and the 
carbonyl of another baclofen molecule whose carboxylic OH group also interacts with  
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one of the same chloride anions that interacts with the ammonium. A bilayer sheet exists 
parallel to the ab plane and these sheets interdigitate in a staggered fashion with each 
other through C-H???Π interactions stacking along the c axis, Figure 4.3. 
 
Figure 4.3: Supramolecular arrangement of (R) Baclofen HCl from the CSD 
Refcode CRBMZC10. 
 
(R,S) Baclofen monohydrate crystals (1) were grown but provided poor 
diffraction data and a suitable/publishable structure was not obtained. Colorless plates 
(Figure 4.4) and needles were simply too small, too thin, or twinned. PXRD data matched 
the previously published data on the monohydrate.34 
 
 
Figure 4.4: Single Crystals of (R,S) Baclofen monohydrate, 1, 20x magnification.   
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4.3.2 Sulfonate Salts of (R,S) Baclofen and their Crystal Structure Descriptions 
The pKa values for (R,S) baclofen are 3.87 and 9.62 for the carboxylic acid and 
amino functional groups respectively.27  It is generally accepted as a guideline that the 
difference in the pKa of the base minus the pKa of the acid must be less than zero if the 
desired outcome is a neutral complex (i.e. cocrystal).35-36  To generate a salt one would 
select two molecules with a difference in pKa of three or more units.11, 37  For the region 
in between (ΔpKa 0-3) the ability to predetermine whether the resulting complex will be 
neutral or charged is difficult.29-30, 38 It should also be noted that pKa is a solution-based 
measurement and does not always translate to solid state chemistry. The pKa values and 
the ΔpKa values for the individual components of the supramolecular assemblies studied 
herein are provided in Table 4.1 and imply salt formation in each case. 
 
Table 4.1: pKa and ΔpKa values. 
Chemical Name  pKa ΔpKa 
Baclofen 9.6227 NA 
p-Phenolsulfonic Acid -2.1939 11.81 
4-Chlorobenzenesulfonic Acid -0.8340 10.45 
 
 (R,S) Baclofen:p-Phenolsulfonate monohydrate, 2: 2 crystallizes in the P21/n space 
group and contains one molecule of baclofen, p-phenolsulfonate, and water in the 
asymmetric unit, Figure 4.5b. An inversion center lies between R and S baclofen 
molecules and each baclofen contains charge assisted hydrogen bonds from the 
ammonium group to three different p-phenolsulfonte molecules via oxygen bonded to 
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sulfur [N11-H11A???O22: N???O 2.829(8) Å, H???O 2.159 Å, N-H???O 156.7 º; N11-
H11B???O22: N???O 2.887(8) Å, H???O 2.201 Å, N-H???O 129.2 º; N11-H11C???O23: 
N???O 2.832(9) Å, H???O 2.062 Å, N-H???O 148.1 º]. The carboxylic OH group on 
baclofen acts as a donor to a water molecule which then inturn hydrogen bonds to three 
different p-phenolsulfonate molecules creating a 3D network, Figure 4.6, [O11-
H11A???O1S: O???O 2.705(8) Å, H???O 1.899 Å, O-H???O 160.0 º; O24-H24???O1S: O???O 
2.964(9) Å, H???O 2.160 Å, O-H???O 160.1 º; O1S-H1SA???O23: O???O 2.712(7) Å, H???O 
1.655 Å, O-H???O 179.0 º; O1S-H1SB???O24: O???O 3.066(9) Å, H???O 2.057 Å, O-H???O 
143.6 º]. The packing arrangement is similar to (R) baclofen HCl in the sense that 
staggered interdigitating phenyl rings are evident. 
 
 
 
   a                                                                    b 
Figure 4.5: a) Single Crystals of Baclofen:p-Phenolsulfonate monohydrate, 2.41         
b) Asymmetric unit for 2. 
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 Figure 4.6: Overall supramolecular packing motif for Baclofen:p-Phenolsulfonate 
monohydrate, 2. 
 
 (R,S) Baclofen:4-Chlorobenzenesulfonate monohydrate, 3: This sulfonate salt 
crystallizes in the C2/c space group as needles, Figure 4.7, and contains one molecule of 
baclofen, 4-chlorobenzenesulfonate, and water in the asymmetric unit. Each different 
proton on the ammonium group interacts with three different 4-chlorobenzenesulfonate 
molecules via oxygen [N1-H1A???O23: N???O 2.911(2) Å, H???O 2.099 Å, N-H???O 111.2 
º; N1-H1B???O22: N???O 2.810(2) Å, H???O 1.984 Å, N-H???O 158.4 º; N1-H1C???O21: 
N???O 2.828(2) Å, H???O 2.034 Å, N-H???O 155.9 º]. The carboxylic acid group of an (R) 
baclofen molecule interacts with two different water molecules via the carbonyl, 
[O2???H41B-O41: O???O 2.769 (2) Å, H???O 2.003 Å, O???H-O 160.41 o] and the OH 
group [O1-H10???O41: O???O 2.535(2) Å, H???O 1.660 Å, O-H???O 169.4 º]. Those water 
molecules then  interact in the same manner with an (S) baclofen molecule, Figure 4.8. 
There are chains created by (R) baclofen molecules interacting by charge assisted 
hydrogen bonding with 4-chlorobenzenesulfonate molecules along the b axis that are 
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connected to similar chains made by (S) baclofen molecules via water in the direction of 
the c axis. These stacked chains create sheets parallel to the bc plane that stack along the 
a axis, Figure 4.9, with 21 screw axis along the b axis in between the sheets.  
Table 4.2 contains crystallographic information pertaining to 2-3. Indeed the 
strategy to use a strong acid to disrupt the intramolecular interaction for baclofen was 
successful. TGA’s for 1-3 can be seen in Appendix 3 and are relatively consistent with 
one water for each. All of them indicate that the water molecules are in channels due to 
the water coming off below 100o C,42 which is confirmed by the structures of 2 and 3. 
The water is held less tightly for 3 since in the TGA weight loss begins the moment 
heating begins from ambient temperature.  
 
 
 
Figure 4.7: Single Crystals of baclofen:4-chlorobenzenesulfonate monohydrate, 3. 
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 Figure 4.8: Supramolecular interactions within the unit cell for baclofen:4-
chlorobenzenesulfonate monohydrate, 3. 
 
 
Figure 4.9: Overall suprmolecular packing motif for baclofen:4-
chlorobenzenesulfonate monohydrate, 3, looking down the b axis. 
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Table 4.2: Crystal structure parameters for salts 2-3. 
 
Compound 2 3 
Chemical 
formula 
C10H13Cl NO2.
C6H5O4S .H2O 
 
C10H13Cl NO2.  
C6H4O3SCl. H2O      
Formula weight 405.89 424.33 
Crystal 
System 
Monoclinic Monoclinic 
Space group P21/n C2/c 
a (Å) 13.837(9) 29.694(4) 
b (Å) 5.584(3) 5.610(8) 
c (Å) 23.750(13) 23.438(3) 
α (o) 90 90 
β (o) 102.381(14) 101.453(2) 
γ (o) 90 90 
Vol (Å3) 1792.5(19) 3826.8(9) 
Dcal (g cm-1) 1.504 1.473 
Z 4 8 
Z’ 1 1 
Reflections 
collected 
3273 8778 
Independent 
reflections    
2231 4303 
Temperature (K) 100 100 
R1 0.0829 0.0424 
wR2 0.2044 0.1071 
GOF 0.98 1.046 
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4.3.3 Pure Water Dissolution 
 In order to dissolve a solid into any solvent system the lattice energy of the solid 
must be over come in order for solvent molecules to interact and solvate each individual 
molecule within the solid. Melting point is sometimes indicative of a general solubility 
trend when dealing with non-ionizable compounds but in the case of salts this can be 
misleading since a salt will typically have a high melting point and a high aqueous 
solubility as in the case of sodium chloride whose melting point is ca. 800o C with an 
aqueous solubility of 360 mg/mL.43 The melting points for the multiple component 
crystalline forms studied here are shown in Table 4.3.  
 
Table 4.3: Melting Points as determined by DSC (See Appendix 3). 
Compound Melting Point of 
Supramolecular 
Complex (oC) 
Melting Point of 
Former (oC) 
Baclofen NA 206-208 
1 NA 198.37 
2 181.47 6.4 
3 190.61 102 
 
Dissolution profiles were measured at 37o C in order to mimic physiological conditions 
although it should be pointed out that these were not USP (United States Pharmacopeia) 
validated protocols. The particle size was controlled by sieves with a range of 53 – 75 μm 
for all dissolution profiles in this and the next two sections. The goal of these dissolution 
experiments herein were aimed at understanding the effect of different pH environments 
with regard to oral and intrathecal dosing. Figures 4.10 and 4.11 show the twenty four 
hour and one hour dissolution profiles for baclofen, 2, and 3 in pure water. Ranking the 
forms from lowest to highest solubility in water results in 3 at 3.88 mg/mL, baclofen at 
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5.01 mg/mL, and 2 at 60.22 mg/mL. The standard deviation for these profiles is low and 
2 is the clear winner if 1st prize is for the greatest solubility. 2 reached a value ca. 20 
times higher than pure baclofen partially due to the decrease in pH to 2.40 initially and 
1.86 at twenty four hours associated with the dissolution of the form since baclofen is 
more soluble under these pH conditions. Table 4.4 includes the pH values recorded. 
Interestingly 3 retained a slightly lower solubility compared to baclofen even over a full 
day despite the fact that the pH decreased to < 3. Both salts did not have greater solubility 
in water which is somewhat surprising considering the sustained lower pH of both salt 
forms in water. It should be pointed out that the only difference between 2 and 3 is an 
alcohol on the aromatic ring of p-phenolsulfonate in 2, which is a chloride in 3. The 
hydrogen bonding capability in 2 fueled by the strong dipole moment for an alcohol is 
likely the cause for such a dramatic difference in solubility with a minor difference in 
molecular structure due to solvation by water.   
 
Table 4.4: pH values for water dissolution. 
Chemical Name  pH Initial pH 24hr 
Baclofen 5.70 6.58 
Bac:p-Phenolsulfonate 2.40 1.86 
Bac:4-Chlorobenzenesulfonate 2.96 2.71 
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 Figure 4.10: 24 hour dissolution profiles in water at 37o C. 
 
 
 
Figure 4.11: 1 hour dissolution profiles in water at 37o C. 
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PXRD data was collected on the solid remaining after dissolution, Appendix 3, for 
baclofen, 2, and 3. For baclofen the powder was partially amorphous and exhibited peaks 
primarily from the original anhydrous material and also 1, which is expected since the 
formation of the hydrate can take days at 25o C. For 2 the post dissolution PXRD pattern 
matched the salt as indicated by the dissolution profile remaining stable. For 3 the post 
dissolution PXRD pattern also matched the salt as indicated by no change in the 
dissolution profile where it could have been possible to precipitate out 1.      
 
4.3.4 pH 1 (0.1 N HCl) Dissolution 
 The dissolution profiles in 0.1 N HCl are shown in Figures 4.12 and 4.13 for 
twenty four hours and 1 hour respectively. The order of lowest to highest solubility is the 
same as in water however the differences between the forms are not the same. The 
solubilities from the low end are; 3 at 9.36 mg/mL, baclofen at 30.79 mg/mL, and 2 at 
59.16 mg/mL. Each solubility dramatically increased in 0.1 N HCl, when compared to 
water, except for 2 which was not significantly different. As it is in the single crystal 
structures, in a solution at a pH of 1 baclofen will be protonated leading to a neutral 
carboxylic acid and an ammonium cation, which in turn causes the molecule to be polar 
and therefore much more water soluble since the zwitterionic structure is defeated. This 
phenomenon explains the increases in solubility under low pH conditions. The solubility 
of 2 remained virtually the same compared to the water dissolution since the pH was 
decreased to < 2 in water after twenty four hours. The pH values for powder dissolution 
in 0.1 N HCl are listed in Table 4.5. 
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Table 4.5: pH values for 0.1 N HCl dissolution. 
Chemical Name  pH Initial pH 24hr 
Baclofen 3.17 3.23 
Bac:p-Phenolsulfonate 1.20 0.97 
Bac:4-Chlorobenzenesulfonate 1.22 0.95 
 
 
 
 
Figure 4.12: 24 hour dissolution profiles in 0.1 N HCl at 37o C. 
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 Figure 4.13: 1 hour dissolution profiles in 0.1 N HCl at 37o C. 
 
 Figures 4.12 and 4.13 are more representative of an environment that an oral 
dosage form would experience since the stomach contains HCl and the average human 
body temperature is 37o C.  The equilibrium solubility has not been reached in 0.1 N HCl 
for baclofen at one day since the curve continues to climb slightly. Interestingly the post 
dissolution solids contained the same phases as in water, as shown in Appendix 3, for 
each compound except for baclofen which was considered more crystalline due to the 
absence of the amorphous hump between 5 and 20o 2 theta. Also, it should be pointed out 
that the HCl salt of baclofen was not indicated by any of the PXRD data.  
 
4.3.5 pH 7 Sodium Phosphate Buffer Dissolution 
 
 Intrathecal administration is currently used for baclofen in cases of severe 
spasticity when the patient is unresponsive to oral therapy or central nervous system 
(CNS) side effects, like sedation, become too great, like sedation for example. Use of an 
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implanted pump allows for a large reduction of dose while maintaining efficacy with 
reduced side effects, however, surgically implanted pumps have their own inherent risks 
which is why they are reserved for patients that do not derive sufficient benefit from oral 
therapy. Plasma levels associated with intrathecal administration are 100 times lower than 
those obtained by oral doses. Current dosing for maintenance therapy associated the 
implanted pumps ranges from 12 - 2003 μg/day. Current refill intervals last ca. sixty to 
ninety days and Albright et al. acknowledges the importance of increasing the solubility 
to reduce pump refill intervals which is highlighted in the intrathecal package insert, 
“certain populations of patients require higher daily doses of baclofen, and obtaining a 
desirable length of time between refills for these patients becomes difficult.”27, 44 
Compounding the problem, strict aseptic conditions must be used during refills to avoid 
bacterial infection. Therefore improvement of the solubility could reduce the frequency 
of refills and overall healthcare costs by reducing physician visits. With this in mind 
solubility of the baclofen salts discovered was tested in a pH 7 buffer since the pH of the 
cerebral spinal fluid (CSF) is 7.30 to 7.3645 and the current formulation for intrathecal 
administration comes in the pH range of 5 - 7.  
 The solubilities from lowest to highest were as follows; 4.10 mg/mL for baclofen, 
5.51 mg/mL for baclofen:p-phenolsulfonate, and 5.81 mg/mL for baclofen:4-
chlorobenzenesulfonate. The dissolution profiles, Figures 4.14 and 4.15 for twenty four 
hours and 1 hour respectively, reveal the salts having relatively low increases compared 
the other solvent systems tested.  
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2 exhibits a profile with an initial boost in solubility that is lost as the concentration is 
moves toward that of pure baclofen after two days. Two day time courses were employed 
for this solvent system since equilibrium was not reached for baclofen after one day in 
0.1 N HCl. 
 
Figure 4.14: 24 hour dissolution profiles in pH 7 buffer at 37o C. 
 
Figure 4.15: 1 hour dissolution profiles in pH 7 buffer at 37o C. 
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 While baclofen seems to have reached equilibrium, 3 appears to be still increasing 
after two days which is surprising considering the small difference in molecular structure 
between 2 and 3. The interaction between ions is clearly stronger with respect to 3 at pH 
7, which could be related to solvation related to the polar nature of the hydroxyl group on 
2 instead of the chlorine on 3. Both salts resulted in ca. 66% increase in solubility 
compared to baclofen after one hour although it is not known why between five and ten 
minutes 3 remained constant. It is possible that this was experimental error although each 
of the three samples agreed as indicated by the very small error bars.  
Compound 3 has the best performance of the two salts since it maintains a higher 
solubility and the concentration of API does not come down although it should be noted 
that longer studies would be necessary to test the ability of this form to sustain long 
periods of time in an intrathecal implanted pump. A pH of 7 remained constant 
throughout the entire dissolution experiment and interactions with buffer are also likely 
affecting the results. Both the formation of phosphate salts and solute-solute interactions 
between all the components present can affect solubility. Further studies would be 
necessary to optimize buffer concentration, which could be lowered since the current 
approved formulation for intrathecal administration exhibits a pH range of 5 - 7. The 
PXRD of the solid remaining after the dissolution experiment can be referred to in 
Appendix 3. For baclofen the PXRD pattern has an amorphous hump and peaks 
corresponding to 1 and baclofen. PXRD data for 2 primarily matches 1 that is slightly 
mixed with baclofen. For 3 the PXRD pattern is not what one would expect after looking 
at the dissolution profile. Since the profile does not decrease towards baclofens value it 
would be expected that the pattern would match the original salt as it does in the other 
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two solvent systems tested, however, the pattern is consistent with 1 containing some 
amorphous content. This could mean that the sustained solubility for baclofen could be 
related to excess 4-chlorobenzenesulfonic acid that is present while 1 is precipitating out 
or phosphate salt formation could be occurring. The excess powder present that is 
amorphous could be the source of baclofen fueling this trend. It would be useful to 
further experiment with 3 to determine if at a certain concentration known to be soluble 
would result in 1 precipitating out over time. 
 
4.4 Conclusions for Baclofen Salts 
 pH has a tremendous effect on the solubility of baclofen but predicting such an 
affect for baclofen sulfonate salts becomes very difficult if not impossible. 
Physiologically speaking some level of aqueous solubility is necessary for an API to be 
effective as a therapeutic agent. pH has a clear effect on ionizable APIs which becomes 
more complicated when zwitterions are involved. The more ionization states a molecule 
possesses the more difficult predicting solubility becomes, but it is possible to control 
which ionization state the API exhibits in the solid state through crystal engineering 
which could be translated to solution. The existing literature shows salts, in general, will 
have a larger increase in aqueous solubility and that cocrystals are more amenable to 
crystal engineering, however, in this case using the strategy of utilizing a strong acid to 
disrupt the uniquely stabilized zwitterionic structure of baclofen was successful. The 
solubility difference pertaining to the sulfonate salts was dramatic in water and at pH 1 
which maintained a trend of lowest to highest solubility of 3, baclofen, then 2. Although a 
twenty fold increase in solubility was achieved with 2 in those solvent systems and p-
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phenolsulfonic acid (median lethal dose (LD50) = 1900 mg/kg in rats) has been used in 
dental applications implying some level of safety,46-47 the solubility was not as 
dramatically increased or stable at pH 7. For intrathecal administration 2 is not a useful 
candidate since the pH range of 5 -7 must be maintained without precipitation of the API 
as 1. 3 was the most interesting since it retained a lower solubility in water and at pH 1 
compared to baclofen but maintained the highest solubility at pH 7. This ca. 66% increase 
in solubility compared to pure baclofen makes 3 a promising candidate to study further 
and could lead to fewer refills for intrathecal pumps reducing surgery associated risks and 
potential precipitation at concentrations above 2 mg/mL, which can clog the pump 
leading to an underdose or overdose due to bursting. The safety of sulfonates in CSF is 
beyond the scope of this work but potential therapeutic benefits may exist. 4-
Chlorobenzenesulfonic acid has an LD50 > 500 mg/kg in rats but toxicological studies 
would be necessary upon further development once the physicochemical properties are 
completely understood. There is a concern of pH reduction in CSF with 3, however, this 
can be controlled either by the natural CSF buffering capabilities45 which utilize 
endogenous bicarbonate or by addition of a bicarbonate buffer to the intrathecal 
formulation.  
 
4.5 Baclofen Lactam Polymorphism: High and Low Z’ Structures 
4.5.1 Background 
Z’ can be strictly defined as the number of formula units in the unit cell divided 
by the number of independent general positions.48 In 2006 structures with a Z’ > 1 
accounted for 8.8% of the CSD 49. Despite their low frequency of occurrence there has 
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been recent interest concerning structures with Z’ > 1 with some debate over their 
occurrence in the CSD50 and why they occur.48, 51-54 Whether high Z’ prime structures are 
simply kinetic structures which have not reached thermodynamic equilibrium or are just 
the best option energetically is an important question, however, a CSD analysis by Steed 
along with other reports claim that some high Z’ structures are in fact the most stable 
form 51-52, 55, which has been supported by computational modeling.56-57 It is recognized 
that high Z’ structures occur more frequently for homochiral molecules such as steroids 
and nucleosides 53 and also for chiral space groups.48 On rare occasions chiral, or Sohnke, 
space groups can be assigned to racemates, i.e. kryptoracemates, which are likely to 
contain pseudosymmetric elements between enantiomers.54    
The appearance of pseudosymmetry in structures with Z’ > 1 has been shown to 
occur 27% of the time, where as for Z’ = 2 structures it occurs 83% of the time.48, 57-58 
Pseudosymmetry, which can be described as molecules or intermolecular aggregates 
coming very close to a symmetry element without actually fulfilling it is likely influenced 
by what has been called “frustration” between favorable packing and highly directional 
(strong) supramolecular synthons.55 It would not be surprising that molecules of a certain 
shape and size simply cannot satisfy either demand completely, which could result in a 
compromise between the two, leading to more than one symmetry equivalent in the 
asymmetric unit and indeed Steed has highlighted the factors that may lead to a high Z’ 
structure48; 1) irregular, non-self complementary shape 2) small number of strong 
intermolecular interacting functionalities 3) frustration between overall packing and 
strong intermolecular interactions and 4) strong self complimentary functionality with a 
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resolved chiral center. Also, when there are multiple energetically favorable 
conformations for a molecule a higher tendency toward polymorphism and Z’ > 1  
structures would be expected. There are a multiple examples containing polymorphic 
systems where at least one of the polymorphs have a Z’ > 1 51-52, 56, 59-64, but there are also 
cases where each structure in a polymorphic set contains a Z’ > 1, as in the case of 
cholesterol 48, 65.  
A case of polymorphism including a high Z’ structure for (R,S) baclofen lactam, 
or (R,S) 4-(4-chlorophenyl)-2-pyrrolidone, Figure 4.16, is presented herein. Baclofen 
lactam is a dehydration product of baclofen and can be isolated as a synthetic 
intermediate on the way to baclofen66 or used for the synthesis of a proposed GABAergic 
prodrug.67 It has also been shown that a lyophilized formulation with baclofen containing 
polyvinylpyrrolidone K30 (PVP K30), a hydrophilic excipient used as a wet binder or 
disintegrant, had a significant effect on the degradation of baclofen to the lactam 68. Form 
I of (R,S) Baclofen lactam has been previously deposited in the CSD (refcode 
ZUWKOR) and exhibits Z’ = 1.69 The R form of baclofen lactam prepared by resolution 
using (2R, 3R)-(+)-tartaric acid was also reported in the same article as Form I. It is 
reported herein how attempts to prepare single crystals of (R,S) baclofen or cocrystals of 
(R,S) baclofen afforded two new polymorphs of the lactam, Forms II and III. 
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Figure 4.16: Baclofen lactam chemical diagram. 
 
 
4.5.2 Synthesis 
 Form II, was prepared by dissolving 300mg of (R,S) baclofen in hot 3-
bromopyridine and the solution was left at room temperature to evaporate. Large 
colorless blocks were present after 128 days.  
 Form III, was prepared by dissolving a 1:2 molar ratio of glutaric acid (92.75mg, 
0.702mmol) to (R,S) baclofen (300mg, 1.40mmol) in hot dimethylformamide (DMF) and 
the solution was left to evaporate at room temperature. Colorless plates and blocks were 
present after 38 days.  
4.5.3 Cambridge Structural Database Statistics 
 The CSD was surveyed for the occurrence of high Z’ structures and the statistics 
are presented in Table 4.6. Z’ > 1 structures account for 8.94% of all structures and 
11.90% of organics. These values are consistent with the of 8.8% and 11.5%, 
respectively, provided by Steed in 2006.49 Steed also reported that 14.6% of crystals that 
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adopt chiral space groups exhibit high Z’ values, as might be expected.70 As Z’ increases 
the occurrence of structures drops off considerably and only 0.08% of structures exhibits 
Z’ > 4. 
 
Table 4.6: CSD statistics for Z’ > 1.71 
Z’ value No restrictions % of total Only organics % of only organics
>  1 46827 8.94 26706 11.90 
>  2 4868 0.93 3133 1.40 
>  3 2542 0.49 1731 0.77 
>  4 441 0.08 322 0.14 
≥ 4 2531 0.48 1726 0.77 
= 4 2090 0.39 1404 0.63 
 
 
A search was undertaken with greater restrictions (3D coordinates determined, R 
≤ 0.05, only organics, and Z’ ≥ 4) to get a more detailed perspective of Z’ ≥ 4 structures, 
Table 4.7. This afforded only 175 hits amounting to 0.17% of the total amount of entries 
with these same restrictions. This value is much lower than the 0.77% in Table 4.6 for Z’ 
≥ 4 (only organics) indicating that as higher standards are applied the occurrence of high 
Z’ structures is even less likely than indicated by the raw search. Each of the 175 entries 
in Table 4.7 was analyzed for chiral centers, for racemates, and for kryptoracemates. It 
was found that 23.30% of Z’ ≥ 4 structures are racemates whereas only 3.43% were 
kryptoracemates, which has been reported to be very rare.54 
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Table 4.7: CSD Refined statistics for Z’ ≥ 4.72 
Total % out of 
104,996 
# Racemates 
(% of total) 
#Kryptoracemates  
(% of total) 
175 0.17 41 (23.30)  6 (3.43) 
 
4.5.4 Crystal Structure Descriptions 
Form II (4) 
 Form II is a racemate that crystallizes in P-1 with four molecules in the 
asymmetric unit. The asymmetric unit is depicted in Figure 4.17 where the bc plane is the 
plane of the page. The four different molecules in the asymmetric unit are labeled A – D. 
Each molecule forms an amide dimer with another baclofen lactam molecule but not 
necessarily with the opposite enantiomer. A (proton at the chiral center is coming toward 
you), B, and D are in the R configuration, while C is in the S configuration.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: 50% probability ORTEP diagram for the asymmetric unit of Form II. 
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The hydrogen bond distances and angles are presented in Table 4.8. A is paired with 
another R molecule (R-R dimer) [N41-H41???O61: N???O 2.849(4) Å, H???O 1.92 Å, N-
H???O 170.0 º], B is paired with C, an S molecule (R-S dimer) [N1-H1???O21: N???O 
2.919(4) Å, H???O 2.09 Å, N-H???O 163.1º; N21-H21???O1: N???O 2.827(4) Å, H???O 1.97 
Å, N-H???O 177.6 º], and D is paired with another R molecule (R-R dimer) [N61-
H61???O41: N???O 2.925(4) Å, H???O 1.96 Å, N-H???O 158.2 º]. These hydrogen bond 
distances are close to that of Form I (2.925 Å), the primary  amide dimer (2.95 Å, see 
Appendix 3), and the secondary amide dimer which includes lactams (2.87 Å, see 
Appendix 3). The B-C (R-S) dimer appears to have a pseudosymmetric center of 
inversion. There are centers of inversion on the corners of the unit cell, the middle of 
each axis, the center of the unit cell, and at the center of each face. These inversion 
centers are between dimeric pairs of S-S and R-R or R-S and R-S. It is rather unusual that 
the R-S pairing is maintained but not around an inversion center as is typical of 
racemates. Figure 4.18 highlights the odd pairing of enantiomers. Selected bond angles 
and distances are provided in Table 4.9. The bond distances and angles around the 
stereogenic carbon atom for A - D range as follows; A: 1.512(5) – 1.536(5) Å and 
101.4(3)o – 118.4(3)o , B: 1.515(4) – 1.560(5) Å and 102.0(3)o – 118.0(3)o, C: 1.463(6) – 
1.537(5) Å and 104.5(3)o – 117.3(3)o, and D: 1.516(5) – 1.556(5) Å and 103.0(3)o – 
118.2(3)o. Each symmetry independent molecule varies slightly from the next but C, 
which is the only S molecule in the asymmetric unit, has a relatively short C-C bond 
between the chiral carbon and the carbon connected to nitrogen in the five member ring. 
This could be a result of packing forces.  
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 Figure 4.18: Pairing between R and S baclofen lactam molecules in Form II. 
 
Form III (5) 
 Form III crystallizes in P21/c and like form I only has one molecule in the 
asymmetric unit. This low Z’ polymorph is a racemate and contains the amide dimer 
observed in Forms I and II with hydrogen bonding parameters as follows; [N1-H2N???O1: 
N???O 2.915(3) Å, H???O 1.91 Å, N-H???O 168.6 º], Table 4.8. The amide dimer is 
depicted in Figure 4.19. 
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 Figure 4.19: Lactam dimer in Form III. 
 
These hydrogen bond distances are close to that of Form I (2.925 Å), the primary amide 
dimer from a CSD survey (2.95 Å, see Appendix 3), and the secondary amide dimer from 
a CSD survey which includes lactams (2.87 Å, see Appendix 3).The bond angles and 
distances, Table 4.8, around the chiral carbon atom range from 103.0(3) – 115.5(3)o and 
1.512(4) - 1.540(4) Å respectively. The bond distances and angles are comparable to 
Forms I and II. The torsion angle (C3-C4-C7-C10) of 123.2(3)o, Table 4.9, is smaller 
than that in Form II but larger than that in Form I. The puckering of the five member ring 
is reminiscent of Form II but the planes of the rings are closer to perpendicular. There is 
an inversion center between R and S molecules and a 21 screw axis along b. Form III was 
obtained in the presence of glutaric acid during an unsuccessful cocrystallization attempt 
with (R,S) baclofen. The heat involved most likely caused the dehydration of baclofen to 
the lactam and the presence of glutaric acid served as an accidental additive affecting 
nucleation of Form III. Additives have been shown to affect the outcome of 
crystallizations, for example there have been failed cocrystal attempts where the cocrystal 
former has impacted polymorphism and even induced high Z’ structures. 60, 63 
Crystallographic data for Forms II and III can be found in Table 4.10. 
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 Table 4.8: Selected bond distances and angles for Forms II (4) and III (5) [Å and °]. 
Bond lengths (Å)                         Bond angles (°) 
_____________________________________________________ 
Form II 
C(4)-C(7)          1.515(4)             C(4)-C(7)-C(8)          118.0(3) 
C(7)-C(8)          1.539(5)             C(4)-C(7)-C(10)        113.0(3) 
C(7)-C(10)        1.560(5)             C(8)-C(7)-C(10)        102.0(3) 
C(24)-C(27)      1.537(5)             C(30)-C(27)-C(28)    104.5(3) 
C(27)-C(30)      1.463(6)             C(30)-C(27)-C(24)    115.9(4) 
C(27)-C(28)      1.528(5)             C(28)-C(27)-C(24)    117.3(3) 
C(44)-C(47)      1.517(5)             C(48)-C(47)-C(44)    118.2(3) 
C(47)-C(48)      1.516(5)             C(48)-C(47)-C(50)    103.0(3) 
C(47)-C(50)      1.556(5)             C(44)-C(47)-C(50)    113.5(3) 
C(64)-C(67)      1.512(5)             C(64)-C(67)-C(68)    118.4(3) 
C(67)-C(68)      1.526(5)             C(64)-C(67)-C(70)    114.8(3) 
C(67)-C(70)      1.536(5)             C(68)-C(67)-C(70)    101.4(3) 
 
Form III 
C(4)-C(7)          1.512(4)             C(4)-C(7)-C(10)       113.3(3) 
C(7)-C(10)        1.538(4)             C(4)-C(7)-C(8)         115.5(3) 
C(7)-C(8)          1.540(4)             C(10)-C(7)-C(8)       103.0(3) 
 
Table 4.9: Selected torsion angles (o) for Forms I, II (4), and III (5). 
________________________________________ 
 
Form II 
A         C(45)-C(44)-C(47)-C(48)            171.7(3) 
B         C(5)-C(4)-C(7)-C(8)                    175.7(4) 
C         C(25)-C(24)-C(27)-C(28)            144.9(4) 
D         C(65)-C(64)-C(67)-C(68)            167.3(4)  
 
Form III 
           C(3)-C(4)-C(7)-C(8)                  -118.3(3) 
                                                 C(3)-C(4)-C(7)-C(10)                 123.2(3) 
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Table 4.10: Crystallographic data for forms II (4) and III (5). 
Compound Form II Form III 
Formula C10H10ClNO C10H10ClNO 
Formula Weight 195.64 195.64 
Crystal System Triclinic Monoclinic 
Space Group P-1 P21/c 
a (Å) 9.7937(10) 10.936(4) 
b (Å) 13.2904(14) 8.932(4) 
c (Å) 16.2963(17) 9.878(4) 
α (ο) 69.985(2) 90 
β (ο) 79.546(2) 90.202(8) 
γ (ο) 68.724(2) 90 
V (Å3 ) 1853.2 (3) 964.9(7) 
Z 2 4 
Z’ 4 1 
D (g cm-1 ) 1.402 1.347 
Temperature (K) 100 (2) 223(2) 
θ range (ο) 1.33 - 28.28 1.86 to 28.28 
Limiting indicies -10 ≤ h ≤ 13, -17 ≤ k ≤ 16, -20 ≤ l ≤ 13 -13 ≤ h ≤ 12, -8 ≤ k ≤ 11, -12 ≤ l ≤ 12
Reflns measd 9112 4571 
Reflns unique / Rint 7342, 0.0189 2114, 0.0394 
Reflns observed 5157 935 
Tmin, Tmax 0.361, 1.000 0.781, 1.000 
Goodness of fit on F2 1.021 0.970 
Completeness to θ 28.28o, 79.8% 28.28o, 88.7% 
R1, w R2   [I>2sigma(I)] R1 = 0.0699, wR2 = 0.1632 R1 = 0.0574, wR2 = 0.1343 
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4.5.5 Conclusions for Baclofen Lactam Polymorphs 
 Forms II and III of (R,S) baclofen lactam both came serendipitously. Form II 
came from an attempt to grow single crystals of pure (R,S) baclofen where the applied 
heat in the presence of 3-bromopyridine caused dehydration of baclofen to the lactam and 
subsequent crystallization. Form II crystals did not form for 128 days therefore whether 
or not this is a kinetic product remains to be seen and requires further study. It is possible 
however that a high Z’ structure can be the most stable form. 55-57 One factor previously 
reported to lead to a high Z’ structure, having a small number of strong intermolecular 
functionalities, is confirmed for Form II. This high Z’ polymorph contains a peculiar 
arrangement of enantiomers and has larger torsion angles than the other polymorphs. Z’ ≥ 
4 structures only account for a mere 0.48% of the CSD and any further discoveries of 
high Z’ structures will add to the understanding of why and how these solid-state 
arrangements come about.  
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Chapter 5: Summary and Future Directions 
5.1 Summary 
 Crystal engineering has become another tool for solid-state chemists in general 
and biological sciences in particular to control self assembly of molecules with biological 
activity and is based upon understanding strong intermolecular interactions. Utilizing 
highly directional and strong hydrogen bonding can be used to affect physicochemical 
properties of materials, especially crystalline pharmaceutical formulations, with emphasis 
upon solubility and subsequent delivery of therapeutic compounds. 
 This contribution has exemplified methodologies to generate new multiple 
component crystalline forms of pharmaceuticals with new properties such as solubility 
and pharmacokinetics. Mechanochemistry with the addition of small amounts of solvent, 
or solvent drop grinding (SDG), has been shown to be consistent with traditional solution 
based crystal growth for the generation of cocrystals with carbamazepine. 
Dimethylformamide and dimethylsulfoxide have been shown to be the most effective 
solvents to grind with and subsequently produce the same cocrystal obtained by solution 
crystallizations. Solvents in which both molecules employed, API and cocrystal former, 
have some solubility have also been shown to successfully generate cocrystalline forms 
via SDG.  
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This method is not only “Green” by nature, using microliter amounts of solvent, but also 
inexpensive and time efficient. These properties make it attractive for crystal form 
screening and the patentability of new crystalline forms drives the pharmaceutical 
industry’s recent interest in this technique.  
 SDG was also successfully used to generate cocrystals with meloxicam, a 
commonly prescribed NSAID for mild to moderate pain. The use of this medicine for 
acute pain could exist if a faster onset formulation was developed. With this in mind ten 
carboxylic acid cocrystals were synthesized, many by slurry methods as well, and their 
respective pharmacokinetics in rats was assessed with a single dose administration via 
oral gavage as a suspension. Structural data in the form of single crystal X-ray diffraction 
data was produced for two of the cocrystals, meloxicam:fumaric acid and 
meloxica:succinic acid. These two structures were isostructural which is not surprising 
considering these two coformers only differ by a double bond. Five of these cocrystals 
outperformed meloxicam in terms of AUC and Cmax. In terms of a faster onset the earliest 
time point recorded was fifteen minutes and the meloxicam:4-hydroxybenzoic acid 
cocrystal exhibited a 2.73 fold increase in serum concentration. The solubility of a largely 
prescribed anti-spastic agent, baclofen, has been affected by the generation of two 
sulfonate salts, one with p-phenolsulfonic acid and one with 4-chlorobenzenesulfonic 
acid. The current intrathecal formulation has limited solubility, 2 mg/mL, at the pH range 
necessary for perispinal administration. This limits the length of time between surgically 
implanted pump refills and any concentration greater than that will lead to precipitation 
of baclofen monohydrate over time. Dissolution profiles were generated in three different 
solvent systems at 37o C, two of which were pH controlled. Pure water powder 
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dissolution resulted in acidic pH and a 20 fold increase in solubility compared to pure 
baclofen for the p-phenolsulfonate salt after twenty four hours with a dramatic increase 
after only one minute. The 4-chlorobenzenesulfonate salt maintained a slightly lower 
solubility over one day compared to baclofen in water although the pH remained less than 
three throughout the study similar to the p-phenolsulfonate salt. For pure baclofen the pH 
range sustained was 5.70 – 6.58 over twenty four hours in water and it is known that a 
zwitterionic state is maintained at this pH range. In 0.1 N HCl the pH remained close to 
one for both salts and the order of least soluble to most soluble remained the same as in 
water, which is unsurprising since an acidic pH was maintained. There was also a 20 fold 
increase in solubility with the p-phenolsulfonate salt, however, pure baclofen was much 
more soluble at this pH due to protonation resulting in disruption of the zwitterionic state 
bringing baclofen to its cationic form. The 4-chlorobenznensulfonate salt was one third 
lower in solubility when compared to baclofen. In pH 7 sodium phosphate buffer the 
order of highest to lowest solubility changed to the 4-chlorbenzenesulfonate salt, p-
phenolsulfonate salt, then baclofen. The magnitude of change was much less dramatic 
and only the 4-chlorobenzenesulfonate salt maintained higher solubility than baclofen, 
which was still increasing after forty eight hours. The p-phenolsulfonate salt decreased 
towards pure baclofen making it unsuitable for further development. More experiments 
are necessary to determine if the 4-chlorobenzenesulfonate salt is safe for intrathecal 
administration and stable over long periods of time without precipitation of baclofen 
monohydrate.  
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 Baclofen lactam polymorphs, Forms II and III, were discovered during crystal 
growth experiments with pure baclofen and cocrystallization attempts with glutaric acid 
respectively. Both forms are conformational polymorphs while Form II has a high Z’of 
four. It was found that only 0.39% of entries in the CSD have a Z’ =  4. The 
conformational flexibility of baclofen lactam enables Form II to have this high Z’ and an 
odd pairing of enantiomers including the presence of pseudosymmetry is exhibited. Form 
II was the result of dehydration of baclofen upon crystallization experiments targeted at 
growing single crystals of pure baclofen. Form III was the result of a failed 
cocrystallization experiment with glutaric acid and, similarly to Form II, the dehydration 
of baclofen to the lactam resulted from heating the solution. Supramolecular synthons for 
Forms II and III are consistent with Form I exhibiting the amide dimer. 
 Multiple component pharmaceutical crystal forms have been shown to be 
produced by multiple methods and these new crystalline entities can have tunable 
physicochemical properties that can lead to tunable pharmacokinetics. These conclusions 
have added tools to basic pharmaceutical sciences and shown that solid-state forms can 
be engineered. New multiple component crystalline forms can help remedy problems 
such as solubility, stability, and bioavailability and even extend the life cycle of currently 
marketed API’s with new patent protection.   
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5.2 Future Directions 
 Supramolecular chemistry has grown as a field impacting both academia and 
industry. It is now well accepted that self assembly of organic and inorganic compounds 
can be rationally designed and controlled based upon the understanding of 
supramolecular interactions. Manipulation of intermolecular forces to obtain desirable 
characteristics has expanded its presence to include multiple facets of industrial 
application. Pharmaceutical sciences in particular has taken a deep interest in optimizing 
and developing novel crystalline forms of active pharmaceutical ingredients (API’s) 
without the use of covalent changes in order to retain desired pharmacological action 
while improving clinical performance. The future of this area will be more focus on 
understanding how the physicochemical properties of novel crystalline materials are 
impacted based of the parameters chosen for design, i.e. which salt or cocrystal former 
will lead to what change. In terms of pharmaceuticals, in vitro – in vivo correlations need 
much more time and effort to understand how the bioavailability and pharmacological 
action will be affected. Utilizing synergistic multiple component pharmaceutical crystal 
forms could lead to lower doses and a subsequent reduction in adverse events. To 
understand these effects more animal studies across multiple species will be required to 
harness the full potential of multiple component pharmaceutical crystal forms including 
but not limited to salts and cocrystals. 
 This manuscript has shown that SDG can be a useful technique for cocrystal 
screening with two BCS class II API’s. In the future this technique can be utilized much 
more frequently and even routinely for crystal form discovery. It is likely that the crystal 
forms discovered will also be amenable to later stage development and processing. This 
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is important with respect to traditional large scale batches for the production of kilogram 
quantities. The fact that multiple solvents can produce the same cocrystal provides the 
chemical engineers more options in the event that a particular solvent is considered 
dangerous or simply fails to be reproducible upon scale up. This method is attractive and 
could become routine due to its cost effectiveness, eco-friendliness, and time efficiency. 
 Two BCS class II compounds have been shown to be amenable to cocrystal 
formation through SDG while corresponding solution based methods produced the same 
cocrystals. Beyond that meloxicam cocrystals have been shown to have tunable PK 
properties compared to the pure API. A carbamazepine cocrystal has also been shown by 
others to have improved PK performance therefore BCS class II compounds in general 
could be future targets for cocrystallization experiments where the goal is tunable PK 
performance and potentially tunable clinical performance. Future work could be aimed at 
using more animal models with various API’s in this class and a broader choice of 
coformer to systematically asses this technology for BCS class II compounds as a group. 
 For the zwitterionic API baclofen the use of strong acids has been used to disrupt 
a conformationaly stabilized zwitterionic state and change its pH dependent solubility. In 
particular it has been revealed that the problem of limited solubility at physiological pH 
can be increased with this strategy. Future work should be done to see if this rationale can 
be used for other zwitterionic API’s with similar limitations. Thereafter or concurrently 
the in vitro data presented here should be tested for correlations with in vivo testing.  
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 By learning from and complimenting nature’s template of non-covalent 
intermolecular interactions the field of cocrystallization will become more and more 
important as the number of non-ionizable lipophilic drug candidates persists. Few 
cocrystal formulations are currently marketed as such and the development of scale up 
and processing will become the next challenge for this area. It is also possible that 
polypeptide based API’s may be stabilized to degradation before they reach their targets 
by manipulating strong hydrogen bonding interactions. Other unstable formulations may 
also benefit from non-covalent modifications. The application of novel drug delivery and 
tunable physicochemical properties could eventually reach a level of predictability in 
order to customize PK profiles for a particular need whether it be controlled release or 
targeted delivery. 
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Appendix 1: Experimental Data for Carbamazepine  
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Figure 1.1A: FT-IR data for SDG with Carbamazepine and 4,4’-Bipyridine. 
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Figure 1.2A: PXRD data for SDG with Carbamazepine and 4,4’-Bipyridine. 
  
 
 
 
 
 
 
 
154 
 
 Tue Jan 24 16:44:13 2006 drw Cbz
 80
 90
 100
%
T
4-aminobenzoic acid
 88
 90
 92
 94
 96
 98
%
T
Tue Feb 14 10:43:56 2006drw 2b-C
 75
 80
 85
 90
 95
%
T
 1000   2000   3000   4000  
Wavenumbers (cm-1)
Cbz
4-Ambz
DMSO
 
Figure 1.3A: FT-IR data for SDG with Carbamazepine and 4-Aminobenzoic Acid. 
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Figure 1.4A: PXRD data for SDG with Carbamazepine and 4-Aminobenzoic Acid. 
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Figure 1.5A: FT-IR data for SDG with Carbamazepine and 2,6-
Pyridinedicarboxylic Acid. 
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Figure 1.6A: PXRD data for SDG with Carbamazepine and 2,6-
Pyridinedicarboxylic Acid. 
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Figure 1.7A: FT-IR data for SDG with Carbamazepine and Benzoquinone. 
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Figure 1.8A: PXRD data for SDG with Carbamazepine and Benzoquinone. 
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Figure 1.9A:FT-IR data for SDG with Carbamazepine and Terephthalaldehyde. 
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Figure 1.10A: PXRD data for SDG with Carbamazepine and Terephthalaldehyde. 
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Figure 1.11A: IR data for SDG with Carbamazepine and Saccharin. 
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Figure 1.12A: PXRD data for SDG with Carbamazepine and Saccharin. 
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Figure 1.13A: Ft-IR data for SDG with Carbamazepine and Nicotinamide. 
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Figure 1.14A: PXRD data for SDG with Carbamazepine and Nicotinamide. 
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Figure 1.15A: IR data for SDG with Carbamazepine and Aspirin. 
 
 
 
Figure 1.16A: PXRD data for SDG with Carbamazepine and Aspirin. 
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Appendix 2: Experimental Data for Meloxicam 
 
 
Figure 2.1A: Melting point correlation between meloxicam cocrystals and 
coformers. 
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Figure 2.2A: PXRD data for 1. 
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 Figure 2.3A: FT-IR data for 1. 
 
 
 
Figure 2.4A: DSC data for 1. 
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Figure 2.5A: PXRD data for 2. 
 
 
 
 
Figure 2.6A: FT-IR data for 2. 
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 Figure 2.7A: DSC data for 2. 
 
 
 
 
 
Figure 2.8A: FT-IR data for 3. 
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Figure 2.9A: [1H] NMR Spectrum For 1:1 Meloxicam:Maleic Acid Slurry in EtOAc. 
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 Figure 2.10A: [1H] NMR Spectrum For 1:2 Meloxicam:Maleic Acid Slurry in EtOAc. 
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Figure 2.11A: [1H] NMR Spectrum For 2:1 Meloxicam:Maleic Acid Slurry in EtOAc. 
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Figure 2.12A: PXRD data for 4. 
 
 
 
 
Figure 2.13A: FT-IR data for 4. 
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 Figure 2.14A: DSC data for 4. 
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Figure 2.15A: PXRD data for 5. 
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 Figure 2.16A: FT-IR data for 5. 
 
 
 
Figure 2.17A: DSC data for 5. 
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Figure 2.18A: PXRD data for 6. 
 
 
 
Figure 2.19A: FT-IR data for 6. 
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 Figure 2.20A: DSC data for 6. 
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Figure 2.21A: PXRD data for 7. 
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Figure 2.22A: FT-IR data for 7. 
Figure 2.23A: DSC data for 7. 
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Figure 2.24A: PXRD data for 8. 
 
 
Figure 2.25A: FT-IR data for 8. 
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Figure 2.26A: DSC data for 8. 
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Figure 2.27A: PXRD data for 9. 
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Figure 2.28A: FT-IR data for 9. 
 
 
 
Figure 2.29A: DSC data for 9. 
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Figure 2.30A: PXRD data for 10. 
 
 
 
 
Figure 2.31A: FT-IR data for 10. 
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Figure 2.32A: DSC data for 10. 
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Appendix 3: Experimental Data for Baclofen and Baclofen Lactam 
 
 
Figure 3.1A: TGA for (R,S) Baclofen Monohydrate. 
 
Figure 3.2A: DSC for (R,S) Baclofen Monohydrate. 
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 Figure 3.3A: TGA for (R,S) Baclofen:p-Phenolsulfonate. 
 
Figure 3.4A DSC for (R,S) Baclofen:p-Phenolsulfonate. 
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 Figure 3.5A: TGA for (R,S) Baclofen:4-Chlorobenzenesulfonate. 
 
Figure 3.6A: DSC for (R,S) Baclofen:4-Chlorobenzenesulfonate. 
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Figure 3.7A: PXRD data for baclofen dissolution. 
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Figure 3.8A: PXRD data for Baclofen:p-Phenolsulfonate dissolution. 
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Figure 3.9A: PXRD data for Baclofen:4-Chlorobenzenesulfonate in pH 7 sodium 
phosphate buffer. 
 
 
Figure 3.10A: Histogram for amide-amide dimer, 1st contact. CSD version 5.31 Aug. 
2010 update with search parameters; 3D coordinates, organics, and R ≤ 0.05. 
Contact between donor and acceptor defined as 2.7 – 3.3 Å. 
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 Figure 3.11A: Histogram for amide-amide dimer, 2nd contact. CSD version 5.31 
Aug. 2010 update with search parameters; 3D coordinates, organics, and R ≤ 0.05. 
Contact between donor and acceptor defined as 2.7 – 3.3 Å. 
 
Figure 3.12A: Histogram for secondary amide- secondary amide dimer (includes 
lactams), 1st contact. CSD version 5.31 Aug. 2010 update with search parameters; 
3D coordinates, organics, and R ≤ 0.05. Contact between donor and acceptor 
defined as 2.5 – 3.1 Å. 
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 Figure 3.13A: Histogram for secondary amide- secondary amide dimer (includes 
lactams), 2nd contact. CSD version 5.31 Aug. 2010 update with search parameters; 
3D coordinates, organics, and R ≤ 0.05. Contact between donor and acceptor 
defined as 2.5 – 3.1 Å. 
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